

World
Cancer
Research
Fund



American
Institute for
Cancer
Research



Continuous
Update
Project

Analysing research on cancer
prevention and survival



Diet, nutrition, physical activity and **lung cancer**

2017

Revised 2018



World
Cancer
Research
Fund International



World
Cancer
Research
Fund UK



Wereld
Kanker
Onderzoek
Fonds



World
Cancer
Research
Fund

世界癌症研究基金會

Contents

World Cancer Research Fund Network	3
1. Summary of Panel judgements	9
2. Trends, incidence and survival	10
3. Pathogenesis	12
4. Other established causes	13
5. Interpretation of the evidence	13
5.1 General	13
5.2 Specific	14
6. Methodology	15
6.1 Mechanistic evidence	16
7. Evidence and judgements	16
7.1 Arsenic in drinking water	17
7.2 Beta-carotene supplements	19
7.3 Vegetables	23
7.4 Fruit	27
7.5 Foods containing carotenoids	30
7.6 Foods containing beta-carotene	32
7.7 Foods containing vitamin C	35
7.8 Foods containing isoflavones	37
7.9 Red meat	39
7.10 Processed meat	41
7.11 Foods containing retinol	43
7.12 Alcoholic drinks	45
7.13 Physical activity	48
7.14 Other	50
8. Comparison with the Second Expert Report	50
9. Conclusions	51
Acknowledgements	52
Abbreviations	54
Glossary	55
References	61
Appendix: Criteria for grading evidence for cancer prevention	67
Our Cancer Prevention Recommendations	71

WORLD CANCER RESEARCH FUND NETWORK

OUR VISION

We want to live in a world where no one develops a preventable cancer.

OUR MISSION

We champion the latest and most authoritative scientific research from around the world on cancer prevention and survival through diet, weight and physical activity, so that we can help people make informed choices to reduce their cancer risk.

As a network, we influence policy at the highest level and are trusted advisors to governments and to other official bodies from around the world.

OUR NETWORK

World Cancer Research Fund International is a not-for-profit organisation that leads and unifies a network of cancer charities with a global reach, dedicated to the prevention of cancer through diet, weight and physical activity.

The World Cancer Research Fund network of charities is based in Europe, the Americas and Asia, giving us a global voice to inform people about cancer prevention.

OUR CONTINUOUS UPDATE PROJECT (CUP)

The Continuous Update Project (CUP) is the World Cancer Research Fund (WCRF) Network's ongoing programme to analyse cancer prevention and survival research related to diet, nutrition and physical activity from all over the world. Among experts worldwide it is a trusted, authoritative scientific resource which informs current guidelines and policy on cancer prevention and survival.

Scientific research from around the world is continually added to the CUP's unique database, which is held and systematically reviewed by a team at Imperial College London. An independent panel of experts carries out ongoing evaluations of this evidence, and their findings form the basis of the WCRF Network's Cancer Prevention Recommendations (see **inside back cover**).

Through this process, the CUP ensures that everyone, including policymakers, health professionals and members of the public, has access to the most up-to-date information on how to reduce the risk of developing cancer.

The launch of the WCRF Network's Third Expert Report, *Diet, Nutrition, Physical Activity and Cancer: a Global Perspective*, in 2018 brings together the very latest research from the CUP's review of the accumulated evidence on cancer prevention and survival related to diet, nutrition and physical activity. **Diet, nutrition, physical activity and lung cancer** is one of many parts that make up the CUP Third Expert Report: for a full list of contents, see **dietandcancerreport.org**.

The CUP is led and managed by World Cancer Research Fund International in partnership with the American Institute for Cancer Research, on behalf of World Cancer Research Fund UK, Wereld Kanker Onderzoek Fonds and World Cancer Research Fund HK.

HOW TO CITE THIS REPORT

This part: World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. **Diet, nutrition, physical activity and lung cancer**. Available at **dietandcancerreport.org**

The whole report: World Cancer Research Fund/American Institute for Cancer Research. *Diet, Nutrition, Physical Activity and Cancer: a Global Perspective*. Continuous Update Project Expert Report 2018. Available at **dietandcancerreport.org**

KEY

References to other parts of the Third Expert Report are highlighted in **purple**.

EXECUTIVE SUMMARY

Background and context

Lung cancer is the third most common cancer worldwide. About 1.8 million new cases of lung cancer were recorded globally in 2012, accounting for 13 per cent of all new cases of cancer [2].

Lung cancer is the most common cause of death from cancer, estimated to be responsible for nearly one in five cancer deaths. Lung cancer survival is mostly determined by the stage at which it is diagnosed, with later-stage diagnosis having poorer survival. In the United States, the five-year survival rate is 17 per cent for lung cancer overall. However, this rises to 55 per cent for lung cancers diagnosed at an early stage.

About 58 per cent of cases of lung cancer worldwide occur in developing countries. In men lung cancer is the most common cancer diagnosed, and the highest lung cancer rates are in Central and Eastern Europe and Eastern Asia. In women lung cancer is the third most common cancer, and the highest rates are in North America, Northern Europe and Eastern Asia [2].

Rates of lung cancer incidence in many developed countries are declining because fewer people are smoking. Conversely, in some countries, including China, South Korea and several countries in Africa, smoking rates are peaking or continuing to increase and the number of new lung cancer cases continues to rise.

In this report from our Continuous Update Project (CUP) – the world's largest source of scientific research on cancer prevention and survivorship through diet, weight and physical activity – we analyse global research on how certain lifestyle factors affect the risk of developing lung cancer. This research includes new studies as well as those included in our 2007 Second Expert Report, *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective* [1].

In addition to the findings in this report, other established causes of lung cancer include the following:

1. Smoking

- Smoking is the main cause of lung cancer. It is estimated that over 90 per cent of cases among men and over 80 per cent among women worldwide are attributable to tobacco use. Passive smoking is also a cause of lung cancer.

2. Previous lung disease

- A history of emphysema, chronic bronchitis, tuberculosis or pneumonia is associated with an increased risk of lung cancer. People with antibodies to *Chlamydia pneumoniae*, a type of bacterium that can cause chest infections, have an increased risk of lung cancer.

3. Other exposures

- Occupational exposure to asbestos, crystalline silica, radon, mixtures of polycyclic aromatic hydrocarbons and heavy metals are associated with an increased risk of lung cancer as well as indoor air pollution from wood and coal burning for cooking and heating.

How the research was conducted

The global scientific research on diet, weight, physical activity and the risk of lung cancer was systematically gathered and analysed, and then independently assessed by a panel of leading international scientists in order to draw conclusions about which of these factors increase or decrease the risk of developing lung cancer.

More research has accumulated on this topic since our 2007 Second Expert Report [1]. In total, this new report analyses 124 studies from around the world, covering nearly 14 million adults and over 122,000 cases of lung cancer.

To ensure consistency, the methodology for the Continuous Update Project remains largely unchanged from that used for our 2007 Second Expert Report [1].

A summary of the mechanisms underpinning all the findings can be found in the Evidence and Judgements section of this report.

Findings

There is strong evidence that:

- There is strong evidence that drinking water containing arsenic increases the risk of lung cancer.
- In current and former smokers there is strong evidence that taking high-dose beta-carotene supplements increases the risk of lung cancer.

There is some evidence that:

- There is some evidence that suggests consuming red meat, processed meat and alcoholic drinks increases the risk of lung cancer.
- In current smokers and former smokers there is some evidence that suggests consuming vegetables and fruit decreases the risk of lung cancer.
- There is some evidence that suggests consuming foods containing retinol, beta-carotene or carotenoids decreases the risk of lung cancer.
- In current smokers there is some evidence that suggests consuming foods containing vitamin C decreases the risk of lung cancer.
- In people who have never smoked there is some evidence suggesting that consuming foods containing isoflavones (constituent of plants with oestrogen-like properties) decreases the risk of lung cancer.
- There is some evidence that suggests being physically active decreases the risk of lung cancer.

Recommendations

Our Cancer Prevention Recommendations – for preventing cancer in general – include maintaining a healthy weight, being physically active and eating a healthy diet. The Cancer Prevention Recommendations are listed on the inside back cover of this report, with full details available in [Recommendations and public health and policy implications](#).

References

- [1] World Cancer Research Fund / American Institute for Cancer Research. *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective*. Washington DC: AICR, 2007. Available from wcrf.org/about-the-report
- [2] Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2015; available from <http://globocan.iarc.fr>

2017	DIET, NUTRITION, PHYSICAL ACTIVITY AND LUNG CANCER		
		DECREASES RISK	INCREASES RISK
STRONG EVIDENCE	Convincing		Arsenic in drinking water ¹ High-dose beta-carotene supplements ²
	Probable		
LIMITED EVIDENCE	Limited – suggestive	Vegetables ³ Fruit ³ Foods containing carotenoids Foods containing beta carotene Foods containing retinol Foods containing vitamin C ⁴ Foods containing isoflavones ⁵ Physical activity	Red meat Processed meat Alcoholic drinks
	Limited – no conclusion	Cereals (grains) and their products; starchy tubers; vegetables (never smokers); fruits (never smokers); dietary fibre; pulses (legumes); citrus fruits; poultry; fish; eggs; milk and dairy products; total meat; total fat; animal fats; plant oils; soft drinks; coffee; tea; preservation, processing, and preparation; carbohydrate; protein; vitamin A; thiamin; riboflavin; niacin; vitamin B6; folate; foods containing vitamin C (former and never smokers); vitamin E; selenium; calcium; copper; iron; zinc; beta-carotene supplements (never and former smokers); alpha-carotene; lycopene; beta-cryptoxanthin, lutein and zeaxanthin; foods containing isoflavones (current and former smokers); plasma hydroxyvitamin D; vitamin C supplements; retinol supplements; multivitamin supplements; patterns of diet; body fatness; energy intake; height	
STRONG EVIDENCE	Substantial effect on risk unlikely		

- 1 The International Agency for Research on Cancer (IARC) has graded arsenic and arsenic compounds as Class 1 carcinogens. The grading for this entry applies specifically to inorganic arsenic in drinking water.
- 2 The evidence is derived from studies using high-dose supplements (20 mg/day for beta-carotene; 25,000 IU/day for retinol) in current and former smokers.
- 3 The evidence applies to current and former smokers only.
- 4 The evidence applies to current smokers only.
- 5 The evidence applies only to individuals who have never smoked.

1. Summary of Panel judgements

Overall, the Panel notes the strength of the evidence that arsenic in drinking water and beta-carotene supplements (high doses in smokers) are causes of lung cancer.

The Continuous Update Project (CUP) Panel judges as follows:

Convincing evidence

Arsenic in drinking water: Consumption of arsenic in drinking water is a convincing cause of lung cancer.

Beta-carotene supplements: Consumption of high-dose beta-carotene supplements is a convincing cause of lung cancer in current and former smokers.

Limited-suggestive evidence

Vegetables: The evidence suggesting that consumption of vegetables decreases the risk of lung cancer in current and former smokers is limited.

Fruit: The evidence suggesting that consumption of fruit decreases the risk of lung cancer in current and former smokers is limited.

Foods containing carotenoids: The evidence suggesting that foods containing carotenoids decrease the risk of lung cancer is limited.

Foods containing beta-carotene: The evidence suggesting that foods containing beta-carotene decrease the risk of lung cancer is limited.

Foods containing retinol: The evidence suggesting that foods containing retinol decrease the risk of lung cancer is limited.

Foods containing vitamin C: The evidence suggesting that foods containing vitamin C decrease the risk of lung cancer in current smokers is limited.

Foods containing isoflavones: The evidence suggesting that foods containing isoflavones decrease the risk of lung cancer in individuals who have never smoked is limited.

Physical activity: The evidence suggesting that physical activity decreases the risk of lung cancer is limited.

Red meat: The evidence suggesting that consumption of red meat increases the risk of lung cancer is limited.

Processed meat: The evidence suggesting that consumption of processed meat increases the risk of lung cancer is limited.

Alcoholic drinks: The evidence suggesting that consumption of alcoholic drinks increases the risk of lung cancer is limited.

For a full description of the definitions of, and criteria for, the terminology of ‘convincing’, ‘probable’ ‘limited–suggestive’, ‘limited–no conclusion’ and ‘substantial effect on risk unlikely’, see the **Appendix** on page 67. The Panel judgements for lung cancer are shown in the matrix on **page 8**.

2. Trends, incidence and survival

The lungs are part of the respiratory system and lie in the thoracic cavity. Air enters the lung through the trachea which divides into two main bronchi, each of which is subdivided into several bronchioles which terminate in clusters of alveoli.

The two main types of lung cancer are small-cell lung cancer and non-small-cell lung cancer (NSCLC); NSCLC accounts for 85 to 90 per cent of all cases of lung cancer and has three major subtypes: squamous cell carcinoma, adenocarcinoma and large-cell carcinoma. Adenocarcinoma and squamous cell carcinoma are the most frequent histologic subtypes, accounting for 50 per cent and 30 per cent of NSCLC cases, respectively [3]. Small-cell lung cancer accounts for 10–15 per cent of all lung cancers; this form is a distinct pathological entity and characterised by aggressive biology, propensity for early metastasis and overall poor prognosis.

Incidence and mortality

Smoking and other exposure to tobacco smoke are the principal causes of lung cancer. Lung cancer patterns are largely determined by exposure to tobacco smoking; pooled estimates indicate over 90 per cent of cases in men are due to smoking and over 80 per cent in women [4], although there is considerable variation by world region. Age-adjusted rates of lung cancer are decreasing in many high-income countries due to decreased smoking rates; however, lung cancer remains the third most common type of cancer worldwide. There were an estimated 1.8 million new cases in 2012 (accounting for 13 per cent of all cases of cancer), 58 per cent of which occurred in less developed regions. The disease remains the most common cancer in men worldwide (1.2 million, 17 per cent of all cancers) and the third most common cancer in women (583,000, 9 per cent of all cancers). In men, the highest estimated, age-standardised, incidence rates occur in Central and Eastern Europe and Eastern Asia. Globally, the lowest incidence rates are observed in middle and western Africa. Incidence rates are generally lower in women and the geographical pattern is different, mainly due to different historical exposure to tobacco smoking. The highest estimated rates in women are in northern America and northern Europe with a relatively high rate in eastern Asia. Again, the lowest rates are observed in western and middle Africa where historically the marketing of tobacco products has been more limited.

Estimated to be responsible for nearly one in five deaths from cancer, lung cancer is the most common cause of death from cancer worldwide (1.59 million deaths, 19.4 per cent of the total) and is the leading cause of death in men in 91 countries and in women in 17 countries [5]. Smoking accounts for about 80 per cent of global lung cancer deaths in men and 50 per cent of the deaths in women [6, 7], though passive smoking may account for a further proportion in women.

Trends

Lung cancer trends are largely the product of changing patterns in prevalence of tobacco consumption, and international variations in lung cancer rates and trends largely reflect differences in the stage and degree of tobacco consumption [8, 9]. Lung cancer rates have been decreasing in men and plateauing in women [10, 11] in several Western countries where tobacco consumption was established and peaked by the middle of the last century, including the United States, the United Kingdom, Canada and Australia. In contrast, in countries where consumption is more recently established and rates of smoking have just peaked or continue to increase, including China, South Korea and several countries in Africa, lung cancer rates are increasing, and they are likely to continue to increase for at least the next few decades, barring interventions to accelerate smoking cessation [8, 12].

Lung cancer trends vary by histological subtype. Although smoking increases the risk of all subtypes of lung cancer, squamous cell carcinoma is more strongly related to smoking and rarely seen in non-smokers whereas adenocarcinoma is seen in both smokers and non-smokers, and is the most common type in never smokers [4, 13, 14]. In men, a recent change of most common cell type from squamous cell to adenocarcinoma has been observed [15], likely related to a decline in the use of unfiltered cigarettes. Adenocarcinoma is responsible for a greater proportion of lung cancer in women than in men, with increasing rates of this subtype observed in both sexes in many high-income settings [16, 17].

Survival

The geographical patterns in lung cancer mortality closely follow those in incidence, owing to the high fatality rates, which are similar across world regions. Lung cancer survival is mostly determined by the disease stage, with later-stage diagnosis having poorer prognosis [18]. Close to 70 per cent of patients with NSCLC present with locally advanced or metastatic disease at the time of diagnosis [19]. The overall prognosis is poor; in the United States the five-year survival rate is 17 per cent (rising to 55 per cent for the 16 per cent of lung cancers diagnosed at an early stage) [20], and in the United Kingdom it is 10 per cent [21]. See **Box 1** for more information.

Box 1. Cancer incidence and survival

The cancer incidence rates and figures given here are those reported by cancer registries, now established in many countries. These registries record cases of cancer that have been diagnosed. However, many cases of cancer are not identified or recorded: some countries do not have cancer registries, regions of some countries have few or no records, records in countries suffering war or other disruption are bound to be incomplete and some people with cancer do not consult a physician. Altogether, this means that the actual incidence of cancer is probably higher than the figures given here.

Most information on cancer survival is for the United States and Europe. Survival rates are generally higher in high-income countries and other parts of the world where there are established services for screening and early detection of cancer as well as well-established treatment facilities. Survival is often a function of the stage at which a cancer is detected and diagnosed.

3. Pathogenesis

Carcinogens in tobacco smoke and other inhaled particles, such as coal tar or asbestos, can interact directly with the DNA of lung cells. Because the whole lung is exposed to inhaled carcinogens, several sites may accumulate different cancerous changes, leading to multiple cancers originating in different types of cells. Chronic inflammation may also play a role in the development of lung cancer, with cancerous changes occurring as a response to exposure to irritants and repeated injury.

Molecular changes in the mucosa of smokers that predispose to cancer are now being identified. Dysplasia and carcinoma in situ are histopathologic changes predictive of future development of invasive carcinoma.

This process may take many years or decades depending upon the exposure to cancer-initiating and cancer-promoting components. People with lung adenocarcinomas may have an associated history of chronic lung disease, such as scleroderma, rheumatoid disease, sarcoidosis or tuberculosis.

4. Other established causes

Tobacco use

Smoking is the principal cause of lung cancer; it is estimated to be responsible for over 90 per cent of cases among men and over 80 per cent among women [4]. Involuntary exposure to tobacco smoke in people who have never smoked ('passive smoking') is also a cause of lung cancer [22].

Environmental exposures

The most important occupational and environmental lung carcinogens include asbestos, crystalline silica, radon, mixtures of polycyclic aromatic hydrocarbons and heavy metals [23], as well as indoor air pollution from burning wood and coal for cooking and heating [24].

Previous lung disease


A history of emphysema (144 per cent increased risk), chronic bronchitis (47 per cent), tuberculosis (48 per cent) or pneumonia (57 per cent) is associated with an increased risk of lung cancer [25].

5. Interpretation of the evidence

5.1 General

For general considerations that may affect interpretation of the evidence, see [Judging the evidence](#).

'Relative risk' (RR) is used in this report to denote ratio measures of effect, including 'risk ratios', 'rate ratios', 'hazard ratios', and 'odds ratios'.



5.2 Specific

Considerations specific to lung cancer include the following:

Confounding

Smoking tobacco is the predominant cause of lung cancer. Smokers tend to have less healthy diets, more sedentary ways of life and lower body weight than non-smokers. Therefore a central task in assessing the results of dietary studies is to evaluate the degree to which observed associations in smokers may be due to residual confounding by cigarette smoking; that is, not a direct result of the dietary exposure examined. For most exposures, studies included in these analyses adjusted for smoking, though this may not completely mitigate the problem. Stratification by smoking status can be useful, but typically the number of lung cancers in never smokers is limited. Moreover, if an association is observed in current smokers but not in never smokers, residual confounding in smokers may be an explanation, but it is also plausible that the factor is only operative in ameliorating or enhancing the effects of cigarette smoke. It is also important to differentiate residual confounding from a true effect limited to smokers. Because smoking is such a strong risk factor for lung cancer, residual confounding remains a likely explanation, especially when the estimated risks are of moderate magnitudes.

The relationship between smoking and body composition presents particular problems in interpretation of observational data in relation to lung cancer. Smokers tend to have lower body mass index (BMI) than non-smokers (except for very heavy smokers), and so lower BMI may appear to be associated with increased risk (and conversely, higher BMI with decreased risk) of smoking-related cancers because of confounding by smoking, and imprecision in ascertainment of exposure to smoking makes residual confounding a likely consequence. Furthermore, despite the tendency toward lower BMI among smokers, they also tend to have greater waist circumference. These anthropometric measures are valuable markers of body composition in observational epidemiology but are not able to precisely characterise the proportions of lean and fat tissue, nor the distribution of body fat. The metabolic consequences of greater body fatness (which are responsible for associations between body composition and cancer risk) may be more pronounced in relation to visceral adiposity, which is not marked by BMI. Furthermore, low BMI may reflect predominant loss of lean rather than fat mass, and this may be a consequence of pre-existing disease or a marker of disease severity. Therefore, current evidence is insufficient to elucidate the complex interactions between body size, shape and composition, and metabolic state (including inflammation and hormonal status) in relation to smoking, other related behaviours and lung cancer risk.

6. Methodology

To ensure consistency with evidence collected and analysed for the Second Expert Report [1], the methodology for reviewing the epidemiological evidence in the Continuous Update Project (CUP) remains largely unchanged. However, on the basis of the experience of conducting the systematic literature reviews (SLRs) for the Second Expert Report, some modifications to the methodology were made. The updated literature search was restricted to Medline and included only randomised controlled trials, and cohort and nested case-control studies. Owing to their methodological limitations, and because of the copious prospective data, case-control studies were not analysed in the CUP Lung SLR 2015.

Where possible for this update, meta-analyses for incidence and mortality were conducted separately. However, analyses combining studies on lung cancer incidence and mortality were also conducted to explore whether this outcome could explain any heterogeneity in the results. Separate meta-analyses were also conducted for men and women, and by geographical location, where possible. Separate estimates were provided for former, current and never smokers when possible; however, this was not possible for all exposures.

Studies reporting mean difference as a measure of association were not included in the CUP Lung SLR 2015, as relative risks estimated from mean differences are not adjusted for confounders and thus are not comparable with adjusted relative risks from other studies.

Non-linear meta-analysis was used when the data suggested that the dose-response curve was non-linear, and when detecting a threshold of exposure might be of interest. Details on the non-linear meta-analyses can be found in the CUP Lung SLR 2015.

The CUP Lung SLR 2015 included studies published up to 30 September 2014. For more information on the methodology, see the full CUP Lung SLR 2015 at **wcrf.org/lung-cancer-slr**.

6.1 Mechanistic evidence

The evidence for mechanisms is summarised under each exposure. These summaries were developed from mechanistic reviews conducted for the Second Expert Report [1], updates from CUP Panel members and published reviews.

Update: The evidence for site specific mechanisms of carcinogenesis has been updated for the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report 2018 (our Third Expert Report, available at dietandcancerreport.org). The evidence is based on both human and animal studies. It covers the primary hypotheses that are currently prevailing and is not based on a systematic or exhaustive search of the literature. A signpost to the relevant section in the Third Expert Report which summarises the updated mechanisms evidence can be found under each exposure within this report.

7. Evidence and judgements

The following sections summarise the evidence identified in the CUP Lung SLR 2015 and provide a comparison with the findings from the Second Expert Report [1] and the Panel's conclusions. They also include a brief description of potential biological mechanisms for each exposure.

For information on the criteria for grading the epidemiological evidence, see the **Appendix** on page 67 in this report. References to studies added as part of the CUP have been included; for details of references to other studies from the Second Expert Report, see the CUP Lung SLR 2015.

7.1 Arsenic in drinking water

(Also see CUP Lung SLR 2015: Section 4.1.2.7.2)

The CUP identified four new publications [26-29]. Ten publications from five studies on arsenic and lung cancer were identified in total (summarised in **Table 1**; see CUP Lung SLR Table 98). From the four recent publications, three were on arsenic in drinking water [26, 28, 29] and one was on dietary arsenic intake from foods [27]. Two studies on arsenic in drinking water were on populations with high exposure to arsenic [26, 28] and one study was from an area with low exposure [29]. The measurement of exposure to arsenic in drinking water was based on arsenic levels in well water. Cumulative exposure was calculated from the amount of water consumed and the years of residence in the area. In one study [27], exposure to dietary arsenic was based on questionnaire data. Four of the studies did not adjust for smoking status [30–33].

The studies from areas with high exposure to arsenic [26, 28] showed a significant increased risk of lung cancer with increasing levels of cumulative exposure to arsenic from drinking water. No significant association with risk of lung cancer was observed in the Danish Cohort Study, which is in a population with low levels of exposure to arsenic in drinking water [29]. One study on arsenic from foods [27] reported a borderline significant dose-response association of total arsenic and inorganic arsenic intake and risk of lung cancer in males. Due to the variability in median arsenic exposure and outcomes across studies, it was not possible to conduct meta-analyses. See **Table 1** (CUP Lung SLR 2015 Table 98).



Table 1: Summary cohort studies – arsenic

Study description	No. cases (No. participants) years of follow-up	Sex	RR (95% CI)	Exposure / Contrast
HIGH-EXPOSURE AREAS				
Chung, 2013 (Taiwan, Arsenic Study) [26]	71 (1,563) 20 years	Mixed	1.47 (0.66-3.31)	≥ 19.5 vs. < 9.1 (µg/L * year)
	43 cases	Men	*SMR 6.05 (4.38–8.15)	
	28 cases	Women	*SMR 7.18 (4.77–10.38)	
Chen, 2010 Taiwan (North-eastern Taiwan cohort) [28]	178 (6,888) 11 years	Mixed	2.08 (1.33–3.27) Ptrend: < 0.01	≥ 10,000 vs. < 400 (µg/L year)
			2.25 (1.43–3.55) Ptrend: < 0.01	≥ 300 vs. < 10 µg/L
Chen, 2004 (South-western and north-eastern Taiwan) [34]	139 (10,591) 8 years	Mixed	3.29 (1.60–6.78)	≥ 700 vs. < 10 µg/L
Nakadaira, 2002 (Nakajo Town Study, Japan) [30]	7 (86) 34 years	Men	11.01	Observed deaths vs. expected
		Women	5.34	Observed deaths vs. expected
Chiou, 1995 (South-western Taiwan cohort) [35]	17 (2,256) 5 years	Mixed	4.01 (1.00–16.12)	High vs. unexposed mg/L
Tsuda, 1995 (Japan 1959-1992) [31]	9 (454) 33 years	Mixed	*SMR 15.69 (7.38–31.02)	≥ 1 ppm
Tsuda, 1989 (Nakajo Japan) [32]	6 (281) 28 years	Mixed	*SMR 1,641 (715–3,634)	≥ 0.5 ppm
Chen, 1988 (Taiwan study) [33]	27 (1,008) 16 years	Mixed	*SMR 1,049	***BFD patients vs. general population
			*SMR 284	***BFD patients vs. residents in BFD-endemic area
LOW-EXPOSURE AREAS				
Baastrup, 2008 (Danish Diet Cancer and Health cohort) [29]	402 (56,378) 10 years	Mixed	**IRR 0.99 (0.90–1.08)	Per 1 µg/L
			**IRR 1.00 (0.98–1.03)	Per 5 mg/L
ARSENIC IN FOODS				
Sawada, 2013 (Japan Public Health Centre study) [27]	685 men, 254 women (90,378) 11 years	Men	1.28 (1.00–1.62) Ptrend: 0.05	102.2 vs. 36.5 µg/day (inorganic arsenic)
		Women	1.37 (0.95–1.98) Ptrend: 0.08	107.6 vs. 37.1 µg/ day (inorganic arsenic)
* SMR: standardized mortality ratio. ** IRR: incident rate ratio. *** BFD: blackfoot disease.				

The CUP Lung SLR 2015 findings were similar to the findings from the 2005 SLR. The CUP Lung SLR 2015 included more cohort studies and more cases of lung cancer.

Mechanisms

The International Agency for Research on Cancer (IARC) has judged arsenic and arsenic compounds to be carcinogenic to humans [36]. Arsenic is genotoxic in humans and acts as a chromosomal mutagen and can also act as a synergistic co-mutagen. Arsenic can result in changes in the methylation of oncogenes or tumour-suppressor genes and also interferes with several enzymes of the haem biosynthetic pathway. In laboratory animals and human cells, exposure to arsenite or arsenate results in generation of reduced oxygen species (free radicals). Arsenic biotransformation is thought to deplete cells of reduced glutathione, leading to a state of oxidative stress characterised by decreased scavenging of free radicals, which can directly damage DNA and induce cell proliferation. Regions where arsenic contamination in drinking water leads to high levels of exposure include some southern Asian countries such as Bangladesh, Cambodia and India; areas in South America including Argentina and Chile; and some parts of China and the United States [37].

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Non-alcoholic drinks](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The overall evidence was generally consistent, showing an increased risk of lung cancer with consumption of drinking water containing arsenic. No meta-analysis was possible. There is robust evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

Consumption of arsenic in drinking water is a convincing cause of lung cancer.

7.2 Beta-carotene supplements

(Also see CUP Lung SLR 2015: Section 5.5.1.2.2)

The CUP identified one new randomised controlled trial (RCT) [38] and two cohort studies [39, 40], giving a total of six RCTs and five cohort studies.

The new RCT [38] reported no significant effect of 50 mg of beta-carotene every other day (RR 1.26 (95% CI 0.80–1.99)) during an average of 9.4 years of treatment.

Five other RCTs were identified in the 2005 SLR. A summary of the results is presented in **Table 2** (CUP Lung SLR 2015 Table 136).

Table 2: Summary of RCTs – beta-carotene supplements

Study name and intervention	No. cases		Trial period RR (95% CI)	Post-trial period
	Intervention	Control		
Women's Antioxidant Cardiovascular Study [38]	41	33	June 1995–Jan 2005	
β-carotene 50 mg every other day vs. placebo			1.26 (0.80–1.99)	
ATBC study, lung cancer incidence [41]	242	209	Apr 1985–Apr 1993	May 1993–Apr 2011
Daily 20 mg β-carotene vs. no β-carotene in male smokers			1.17 (1.02–1.33)	1.04 (0.96–1.11)
CARET study, lung cancer incidence [42]	5.92/ 1,000 person years	4.62/ 1,000 person years	1985–Jan 1996	Feb 1996–Dec 2001
Daily β-carotene (30 mg) and retinyl palmitate (25,000 IU) current or former smokers			1.28 (1.04–1.57)	1.12 (0.97–1.31)
Australian cohort of asbestos workers [43]	6	4	Jun 1990–May 1995	
30 mg/day β-carotene vs. 25,000 IU/day retinol			1.50 (0.43–5.28)	
Physicians Health Study (PHS) [44]	85	93	Jun 1982–Dec 1995	
50 mg β-carotene on alternate days vs. placebo group			0.9 (0.7–1.2)	
Women's Health Study [45]	30	21	Apr 1993–Jan 1996	Feb 1998
50 mg of β-carotene every other day for 2 years (women)				1.43 (0.82–2.49)

Both the ATBC and CARET studies reported significant increased risk of lung cancer during the supplementation period, but at follow-up the effect was reduced and no longer statistically significant.

In the ATBC study, beta-carotene supplementation in those smoking 20+ cigarettes daily was associated with a 25 per cent increased risk of lung cancer (RR = 1.25 (95% CI, 1.07–1.46)) over those smoking 5–19 cigarettes daily, in whom no significant association was observed (RR = 0.97 (95% CI, 0.76–1.33)). Similarly, beta-carotene supplementation in those who consumed 11 grams of ethanol or more was associated with a significant increased risk of lung cancer (RR = 1.35 (95% CI, 1.01–1.81)) compared with the effect of supplementation in lower-alcohol consumers.


In the CARET study, risk of lung cancer was especially elevated in those who had the intervention as well as exposure to either asbestos or smoking (at least 20 pack-years), although neither subgroup was statistically significant.

In the PHS, the risk related to beta-carotene consumption was similar for each smoking category in subgroup analyses.

Four of five cohort studies reported non-significant associations. One [39], a Danish prospective study in men and women, showed a significant increase in lung cancer risk per 5,000 µg/day of beta-carotene supplement (the comparison of > 13,500 vs. 0 µg/day was not significant). A summary of the results from the cohort studies is presented in **Table 3** (CUP Lung 2015 SLR Table 137).

Table 3: Summary of cohort studies – beta-carotene supplements

Study	Increment/ Contrast	RR (95% CI)	No. cases	Factors adjusted for
Virtamo, 2014 ATBC [46]	Beta-carotene vs. no beta-carotene	1.04 (0.96–1.11)	2,881	Age, smoking (number cigarettes/day), alcohol consumption, BMI
Roswall, 2009 Denmark Cohort [39]	Per 5,000 µg/day	1.64 (1.20–2.23)	721	Age; sex; supplements of folate, vitamin C and vitamin E; smoking status, intensity, duration; passive smoking; smoking cessation; work exposure to carcinogenic substances
	> 13,500 vs. 0 µg/ day	1.56 (0.58–4.25)		
Satia, 2009 Vitamins And Lifestyle (VITAL) cohort Study [40]	> 1,200 µg /day vs. no use men	1.10 (0.71–1.70)	297	Age; sex; BMI; years of smoking, pack-years and pack-years squared; fruit and vegetable intake; physical activity; supplemental vitamin E use
	> 1,200 µg /day vs. no use women	1.49 (0.76–2.58)	224	
Michaud, 2000 Health Professionals Follow-up Study [47]	Use vs. non-use	0.82 (0.36–1.85)	275	Age (5-year categories), smoking status, time since quitting, age at start of smoking quintiles of energy intake, time period
Michaud, 2000 Nurses' Health Study [47]		1.23 (0.55–2.76)	519	



Genotype and beta-carotene

As reported in the Second Expert Report [1] there is an interaction between beta-carotene, smoking and genotype. Glutathione-S transferase 1 and 2 are carcinogen-detoxifying enzymes. People without or with less active forms of these enzymes are less able to metabolise certain toxins than others and have higher risk of some cancers, particularly if they are smokers. In the ATBC study, among those not supplemented with beta-carotene, the relative risk of lung cancer among those with the glutathione-

S-transferase variant GSTM1 who smoked more than 42 cigarettes per day compared with those who smoked fewer than 37 cigarettes per day was not significant, while in those without the GSTM1 variant the relative risk for higher compared with lower smoking was RR = 8.2 (95% CI 2.2–29.8). In those who received beta-carotene supplements, the relative risk of lung cancer from smoking more than 42 compared with fewer than 37 cigarettes daily was RR = 3.6 (95% CI 1.1–11.1) in those with the GSTM 1 variant, compared with RR = 6.0 (95% CI 1.9–19.1) among those without. In another study of Chinese tin miners at high risk of lung cancer, after adjusting for age and smoking habits, those with the wild-type Arg/Arg genotype in the XRCC1 gene had a RR of lung cancer of 3.0 (95% CI 1.3–7.1) comparing the highest and lowest tertiles of serum beta-carotene (190–900 µg/l compared with < 90 µg/l), while no significant association between lung cancer risk and serum beta-carotene was seen in those with the heterozygous or homozygous Arg/Trp or Trp/Trp variants [48].

Mechanisms

An adverse effect of higher than physiological blood or tissue concentrations of beta-carotene is plausible. In one animal study, low-dose beta-carotene was protective against smoking-induced changes in p53, whereas high doses promoted these changes [49]. In addition, the complex nature of naturally occurring carotenoids raises the possibility that the protective associations are not due simply to the specific agent, but rather to interactions with other carotenoids present in dietary exposure [50], or other associated dietary or health-related behaviours.

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Other dietary exposures](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

There is strong evidence from good-quality trials, generally consistent with cohort studies. An interaction between smoking, genetics and beta-carotene is apparent; the adverse effect of beta-carotene supplements is seen mainly among heavy smokers, and in particular a subgroup characterised by genetic variation in GSTM. The evidence that high-dose beta-carotene supplements cause lung cancer in current and former smokers is convincing. There is robust evidence for mechanisms operating in humans. The CUP Panel concluded the following:

High-dose beta-carotene supplements are a convincing cause of lung cancer in current and former smokers.

7.3 Vegetables

(Also see CUP Lung SLR 2015: Sections 2.2.1, 2.2.1.2 and 2.2.1.4)

The CUP identified five new or updated studies (10 publications) [51-57], giving a total of 24 studies (32 publications) reviewing the evidence for vegetables and lung cancer (see CUP Lung SLR 2015 Tables 15 and 16 for a full list of references). Of 16 studies reporting on lung cancer incidence, 11 reported inverse associations, three of which were significant, three reported non-significant positive associations and two reported inconsistent results for men and women when comparing the highest and lowest categories of intake. Of five studies reporting on lung cancer mortality, three showed inverse associations and one showed a positive association; none of these results were significant. One study reported inconsistent results for men and women when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 11).

Twenty of the 24 studies were included in the dose-response meta-analysis ($n = 12,563$ cases), which showed a statistically significant six per cent decreased risk per 100 grams of vegetables per day (RR 0.94 (95% CI 0.89–0.98); see CUP Lung SLR 2015, Figure 13). Moderate heterogeneity ($I^2 = 48\%$) was observed that was not explained in analyses stratified by sex, smoking or geographic location, but appears to be due to the size of the effect.

There was evidence of a non-linear relationship ($p < 0.01$), with decreasing risks for intakes up to 300–400 grams per day and no further decrease for higher intake levels (CUP Lung SLR 2015 Figure 20 and Table 17). There was evidence of small study bias with Egger's test ($p < 0.01$). The asymmetry was driven by a small Japanese study reporting on very low intakes (see CUP Lung SLR 2015 Figure 14).

When stratified by smoking status, the dose-response meta-analysis showed a 12 per cent decreased risk per 100 grams per day in current smokers (RR = 0.88 (95% CI 0.79–0.99)). No significant associations were observed for former or never smokers (see **Table 4** and CUP Lung SLR 2015 Figure 18).

Table 4: Summary of CUP 2015 stratified dose-response meta-analysis – vegetables

Analysis	Increment	RR (95% CI)	I^2	No. Studies	No. Cases
Current smokers	Per 100 g/day	0.88 (0.79–0.99)	81%	6	6,520
Former smokers	Per 100 g/day	0.97 (0.91–1.05)	25%	4	3,771
Never smokers	Per 100 g/day	1.00 (0.91–1.10)	0%	5	680

All studies included in the dose-response analysis were adjusted for age, sex and smoking status. Most studies (18 out of 19 studies) also adjusted for intensity and duration of smoking and other smoking variables.

Three studies were not included in any of the CUP analyses; two did not report confidence intervals [58, 59] and one did not report sufficient data [60].

The CUP findings are similar to those from the 2005 SLR, which showed a significant inverse association per 80 grams of vegetables consumed per day (RR = 0.95 (95% CI 0.92–0.98)) for 10 studies. The CUP update includes more than double the number of studies and over 5,000 more cases of lung cancer. No analysis by smoking status was possible for the 2005 SLR.

Published pooled analyses and meta-analyses

One published pooled analysis of cohort studies on vegetables and lung cancer risk was identified in the CUP Lung SLR 2015. No significant associations were observed in the pooled analysis when comparing the highest with the lowest vegetable consumers in current, former or never smokers. When the studies identified by the CUP 2015 (but not in the pooled analysis) were combined with the results of the pooled analysis, a significant inverse association was observed overall and in current smokers. Results from the CUP and the published pooled-analysis are presented in **Table 5**.

Table 5: Summary of CUP 2015 meta-analysis and published pooled analysis – vegetables

Analysis	Increment/ Contrast	RR (95% CI)	I ² or P- value	No. Studies	No. Cases	Sub-group
2015 CUP	Per 100 g/day	0.94 (0.89–0.98)	48%	20	12,563	
Pooling Project of cohort studies [61]	Q5 vs. Q1	0.88 (0.78–1.00)	0.76	7	3,206	
	Q4 vs. Q1	0.86 (0.74–1.00)	0.85	5	1,915	Current smokers
		0.97 (0.76–1.24)	0.30		981	Former smokers
		0.90 (0.58–1.40)	0.35		259	Never smokers
CUP additional analysis: pooled analyses of Pooling Project of cohort studies [61] combined with all studies from the CUP	Highest vs. lowest	0.93 (0.88–0.98)	0%	24*	18,927	
		0.88 (0.80–0.97)	32%	10	8,435	Current smokers
		0.98 (0.83–1.16)	55%	8	4,752	Former smokers
		0.96 (0.76–1.20)	0%	9	939	Never smokers

*Three overlapping studies [62, 63] in CUP and pooled analysis.

Other vegetable exposures

The CUP Lung SLR 2015 conducted stratified dose-response meta-analyses for green leafy vegetables by smoking status. A significant inverse association was observed in former smokers, and no significant association was observed in current and never smokers (see **Table 6** and CUP Lung SLR 2015 Figure 33).

Table 6: Summary of CUP 2015 meta-analysis – green leafy vegetables

Analysis	Increment	RR (95% CI)	I ²	No. Studies	No. Cases
2015 CUP	Per 50 g/day	0.89 (0.79–1.00)	50%	8	5,732
Current smokers	Per 50 g/day	0.83 (0.66–1.06)	44%	4	1,388
Former smokers	Per 50 g/day	0.63 (0.41–0.95)	28%	3	425
Never smokers	Per 50 g/day	0.96 (0.76–1.22)	0%	4	591

Mechanisms

Non-starchy vegetables provide many potentially cancer-preventive substances, including several nutrients (such as pro-vitamin A carotenoids and vitamin C) and dietary fibre, as well as phytochemicals (such as glucosinolates, dithiolthiones, indoles, chlorophyll, flavonoids, allylsulphides and phytoestrogens). Phytochemicals might influence cancer risk through multiple mechanisms, including antioxidant activity, modulation of detoxification enzymes, stimulation of the immune system, antiproliferative activity, ligand-dependent signalling through retinoid receptors and/or modulation of steroid hormone concentration and hormone metabolism. Non-starchy vegetables are also a source of folate, which plays an important role in synthesis and methylation of DNA. Abnormal DNA methylation has been linked to aberrant gene expression and also to cancers at several sites and may be particularly important in rapidly dividing tissues. It is difficult to unravel the relative importance of each constituent and likely that a protective effect may result from a combination of influences on several pathways involved in carcinogenesis [1].

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Wholegrains, vegetables and fruit](#) (Appendix – Mechanisms) for the updated mechanisms summary.



CUP Panel's conclusion:

The evidence for consumption of vegetables was limited but generally consistent. The dose-response meta-analysis showed a significant decreased risk of lung cancer, however, moderate heterogeneity was observed and there was also evidence of small study bias. Decreased risk was observed for former and current smokers, which was significant for current smokers. There was evidence of a non-linear dose-response of lung cancer and vegetable intake but only for intakes up to 300–400 grams per day. Although studies adjusted for smoking, there is the potential for residual confounding due to smoking. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that higher consumption of vegetables decreases the risk of lung cancer in current and former smokers is limited.

7.4 Fruits

(Also see CUP Lung SLR 2015: Sections 2.2.2 and 2.2.2.1)

The CUP identified six new or updated studies (11 publications) [51, 53-57, 64-68], giving a total of 30 studies (44 publications) reviewing the evidence for fruits and lung cancer (see CUP Lung SLR 2015 Tables 33 and 34 for a full list of references). Of 17 studies reporting on lung cancer incidence, 15 reported inverse associations, six of which were significant, and two studies reported non-significant positive associations when comparing the highest and lowest categories of intake. All eight studies reporting on lung cancer mortality showed inverse associations, two of which were significant when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 37).

Twenty-three of the 30 studies were included in the dose-response meta-analysis ($n = 14,506$ cases), which showed a statistically significant eight per cent decreased risk per 100 grams of fruit per day (RR 0.92 (95% CI 0.88–0.95); see CUP Lung SLR 2015 Figure 39). High heterogeneity ($I^2 = 57\%$) was observed that appears to be explained by the size of the effect. The overall association remained statistically significant in influence analysis.

There was evidence of a non-linear association ($p < 0.01$). Non-linear analysis showed that risk of lung cancer decreased for intakes up to 200–300 grams per day, with no further decrease for higher intake levels (CUP Lung SLR 2015 Figure 46 and Table 35). There was evidence of small study bias with Egger's test ($p < 0.01$). The funnel plot shows that the smaller studies identified reported stronger inverse associations than the average and that no small studies reported positive associations (see CUP Lung SLR 2015 Figure 40).

When stratified by smoking status, the dose-response meta-analysis showed a nine per cent decreased risk per 100 grams of fruit per day in current smokers (RR = 0.91 (95% CI 0.85–0.98). No significant associations were observed for former or never smokers (see **Table 7** and CUP Lung SLR 2015 Figure 44).

Table 7: Summary of CUP 2015 stratified dose-response meta-analysis – fruits

Analysis	Increment	RR (95% CI)	I ²	No. Studies	No. Cases
Current smokers	Per 100 g/day	0.91 (0.85–0.98)	57%	9	7,141
Former smokers	Per 100 g/day	0.97 (0.92–1.02)	0%	5	3,828
Never smokers	Per 100 g/day	1.03 (0.97–1.09)	0%	8	1,260

All studies included in the dose-response analysis were adjusted for age, sex and smoking status. Most studies (21) adjusted for intensity, duration of smoking and other smoking variables in addition to smoking status. When the analysis was restricted to these studies, the overall association remained the same.

Three studies were not included in any of the CUP analyses, two due to not reporting confidence intervals [58, 59] and one due to not reporting sufficient data [60].

The CUP findings are similar to those from the 2005 SLR, which showed a significant inverse association per 80 grams of fruit consumed per day (RR = 0.94 (95% CI 0.90–0.97)) for 14 studies. The CUP update includes nine more studies and almost double the number of cases.

Published pooled analyses and meta-analyses

One published pooled analysis of cohort studies on fruit and lung cancer was identified in the CUP Lung SLR 2015 [61]. The pooled analysis reported inverse associations when comparing the highest with the lowest fruit consumers, which was significant in current smokers. When the studies identified by the CUP 2015 (but not in the pooled analysis) were combined with the results of the pooled analysis, inverse associations were observed which were significant for current and former smokers. Results from the CUP and the published meta-analyses are presented in **Table 8**.



Table 8: Summary of CUP 2015 meta-analysis and published pooled analysis – fruit

Analysis	Increment/ Contrast	RR (95% CI)	I ² or P- Value	No. Studies	No. Cases	Sub-group
2015 CUP	Per 100 g/day	0.92 (0.88–0.95)	57%	23	14,506	
Pooling Project of cohort studies [61]	Q5 vs. Q1	0.77 (0.67–0.87)	0.56	7	3,206	
	Q4 vs. Q1	0.82 (0.68–0.99)	0.13	5	1,915	Current smokers
		0.85 (0.69–1.05)	0.49	5	981	Former smokers
		0.59 (0.34–1.04)	0.09	5	259	Never smokers
CUP additional analysis: pooled analyses of Pooling Project of cohort studies [61] combined with all studies from the CUP	Highest vs. lowest quantile	0.81 (0.75–0.87)	23%	28*	14,783	
		0.83 (0.75–0.92)	16%	13	6,280	Current smokers
		0.89 (0.81–0.99)	0%	9	3,790	Former smokers
		0.91 (0.71–1.17)	33%	12	2,184	Never smokers
*Three overlapping studies [62, 63] in CUP and pooled analysis.						

Mechanisms

Fruit is a source of nutrients, such as vitamin C and a diverse array of phytochemicals, such as carotenoids, phenols and flavonoids. In addition, flavonoids found in fruit modular cytochrome P450 enzyme systems are involved in the metabolism of carcinogens [69]. It is difficult to unravel the relative importance of each constituent, and it is likely that any protective effect may result from a combination of influences on several pathways involved in lung carcinogenesis.

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Wholegrains, vegetables and fruit](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

Overall the evidence was reasonably consistent. The dose-response meta-analysis showed a significant decreased risk of lung cancer although high heterogeneity was observed. Non-linear analysis showed that risk of lung cancer decreased for intakes up to 200–300 grams per day with no further decreased risk beyond that amount.

Decreased risk was observed for former and current smokers, which was significant for current smokers. Although studies adjusted for smoking, there is the potential for residual confounding due to smoking. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that greater consumption of fruit decreases the risk of lung cancer in current and former smokers is limited.

7.5 Foods containing carotenoids

(Also see CUP Lung SLR 2015: Sections 5.5.2.5 and 5.5.2.1)

The CUP identified one new study [53], giving a total of nine studies (10 publications) reviewing the evidence for dietary total carotenoids and lung cancer (see CUP Lung SLR 2015 Tables 173 and 174 for a full list of references). All five studies reporting on lung cancer incidence showed inverse associations, one of which was significant when comparing the highest and lowest categories of intake. Of two studies reporting on lung cancer mortality, one reported a non-significant inverse association and one reported a significant inverse association in men and a non-significant inverse association in women when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 191).

Seven of the nine studies were included in the dose-response meta-analysis ($n = 4,491$ cases), which showed a two per cent decreased risk per 1,000 micrograms of dietary total carotenoids per day (RR 0.98 (95% CI 0.97–0.99); see CUP Lung SLR 2015 Figure 192). There was evidence of moderate heterogeneity ($I^2 = 37\%$, $p_{\text{heterogeneity}} = 0.16$).

There were not enough studies to do stratified analysis by smoking status. In one study [53], an inverse association was observed among heavy smokers only, and not in non-smokers or light smokers. Two other studies [70, 71] reported no inverse association in either current smokers (light or heavy) or non-smokers. Two studies on smokers or populations exposed to asbestos [72, 73] did not report significant associations.


Results were not significant when stratified by men (RR = 0.98 (95% CI 0.96–1.00)) or women (RR = 0.99 (95% CI 0.98–1.00)) respectively; see CUP Lung SLR 2015 Figure 194).

All studies adjusted for at least smoking status, all except for one [70] adjusted for intensity, duration of smoking and other smoking variables.

The 2005 SLR also found a significant inverse association but included only two studies in the dose-response meta-analysis. The CUP update includes more studies and cases.

Published pooled analyses and meta-analyses

No pooled analyses were identified. One published meta-analysis of cohort studies on total carotenoids intake and lung cancer risk was identified in the CUP Lung SLR 2015 [74]. A significant inverse association was reported per 1,000 μg per day (RR = 0.98 (95% CI 0.97–0.99), $I^2 = 0\%$).



Serum total carotenoids

The CUP identified one new study [75], giving a total of five studies (seven publications) reviewing the evidence for serum total carotenoids and lung cancer (see CUP Lung SLR 2015 Tables 178 and 179 for a full list of references). Two studies reporting on lung cancer incidence showed non-significant inverse associations when comparing the highest and lowest levels. Of three studies reporting on lung cancer mortality, two reported inverse associations, one of which was significant, and one reported a non-significant positive association when comparing the highest and lowest levels (see CUP Lung SLR 2015 Figure 195).

There were not enough data to do stratified analysis by smoking status.

No analysis was conducted in the 2005 SLR.

Published pooled analyses and meta-analyses

No pooled analyses were identified. One published meta-analysis of cohort studies on serum total carotenoids and lung cancer risk was identified in the CUP Lung SLR 2015 [74]. A significant inverse association was reported per 0.75 µmol/L (RR = 0.64 (95% CI 0.46–0.88), $I^2 = 0\%$).

Mechanisms

Several of the carotenoids are retinol (vitamin A) precursors and other metabolites may interact with various members of the steroid receptor superfamily. The pro-vitamin A carotenoids may be converted to retinol where they function in cellular differentiation, immunomodulation and activation of carcinogen-metabolising enzymes [76, 77]. Carotenoids at physiological concentrations may also protect cells and tissues from certain types of oxidant stress and the production of free radicals that may cause DNA damage.

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Wholegrains, vegetables and fruit](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence for consumption of foods containing carotenoids was limited but generally consistent. The dose-response meta-analysis of dietary total carotenoid intake showed a significant decreased risk of lung cancer per 1,000 micrograms per day. No analysis was possible by smoking status. Smoking may affect serum carotenoid levels. Residual confounding could not be excluded. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that foods containing carotenoids decrease the risk of lung cancer is limited.

7.6 Foods containing beta-carotene

(Also see CUP Lung SLR 2015: Sections 5.5.1.2.1 and 5.5.1.2.3)

Dietary beta-carotene

The CUP identified one new study [39], giving a total of 15 studies (19 publications) assessing dietary beta-carotene and lung cancer (see CUP Lung SLR 2015 Tables 134 and 135 for a full list of references). Of 12 studies reporting on lung cancer incidence, seven reported inverse associations, two of which were significant. Three reported non-significant positive associations. One study reported no association and one study showed a non-significant inverse association in women and a non-significant positive association in men when comparing the highest and lowest categories of intake. Both studies reporting on dietary beta-carotene and lung cancer mortality showed non-significant inverse associations when comparing the highest and lowest categories of intake (see CUP Lung SLR Figure 159).

Thirteen studies were included in the dose-response meta-analysis ($n = 7,560$ cases), which showed no significant association (RR 0.99 (95% CI 0.98–1.00) per 700 μg per day) (CUP Lung SLR 2015 Figure 160). Low heterogeneity was observed ($I^2 = 5\%$).

When stratified by smoking status, no significant associations were observed in current, former or never smokers (see CUP Lung SLR 2015 Figure 162).

One study [78] was not included in any of the CUP analyses because it reported insufficient data.

All studies adjusted for intensity, duration of smoking and other smoking variables in addition to smoking status, except one study [70] that was adjusted only for smoking status.

The CUP findings, like the 2005 SLR, showed no significant association.

Published pooled analyses and meta-analyses

Results from one published pooled analysis [79] and one published meta-analysis [74] were identified in the CUP Lung SLR 2015. The pooled analysis reported no significant association (see **Table 9**). The meta-analysis reported no significant associations for both the continuous and the highest versus lowest analyses (RR 0.99 (95% CI 0.98–1.00) and RR 0.92 (95% CI 0.83–1.01)). Results from the CUP meta-analysis and published pooled analysis are presented in **Table 9**.



Table 9: Summary of CUP 2015 meta-analysis and published pooled analysis – foods containing beta-carotene

Study	Increment/ Contrast	RR (95% CI)	I ²	No. Studies	No. Cases
CUP Lung SLR 2015	700 µg/day	0.99 (0.98–1.00)	5%	13	7,560
Männistö 2004 [79]	Q5 vs. Q1	0.98 (0.87–1.11)	-	7	3,155

Serum beta-carotene

The CUP identified two new studies, giving a total of 17 studies (20 publications) assessing serum beta-carotene and lung cancer (see CUP Lung SLR 2015 Tables 141 and 142 for a full list of references). Of nine studies reporting on lung cancer incidence, five reported an inverse association, three of which were significant. Two studies reported positive associations, one of which was significant. One study reported inconsistent results by smoking status and one study showed a significant inverse association in men and non-significant positive association in women when comparing the highest and lowest levels. Of the five studies reporting on lung cancer mortality, three reported non-significant inverse associations, one reported a non-significant positive association and one reported inverse associations in men and women, significant in men only when comparing the highest and lowest levels (see CUP Lung SLR 2015 Figure 166).

Thirteen studies were included in the dose-response meta-analysis ($n = 2,958$ cases), which showed a significant eight per cent decreased risk per 10 micrograms per 100 millilitres (RR 0.92 (95% CI 0.87–0.97)) (see CUP Lung SLR 2015 Figure 167). Moderate heterogeneity was observed ($I^2 = 40\%$, $p_{\text{heterogeneity}} = 0.10$). There were not enough data to stratify by smoking status.

Two studies [80, 81] were not included in any of the CUP analyses because they reported insufficient data.

All studies adjusted for intensity, duration of smoking and other smoking variables in addition to smoking status.

The findings from the CUP Lung Cancer SLR 2015 are stronger than those reported in the 2005 SLR, which included five studies and reported a non-significant inverse association (RR 0.97 (95% CI 0.93–1.02)).

Published pooled analyses and meta-analyses

No pooled analyses were identified. One published meta-analysis of cohort studies on serum beta-carotene and lung cancer risk was identified in the CUP Lung SLR 2015 [74]. No significant association was reported per 0.1 µmol/L (RR 0.95 (95% CI 0.87–1.03), $I^2 = 72\%$).

Mechanisms

Many of the carotenoids, including beta-carotene, are pro-vitamin A carotenoids and on central cleavage form two molecules of vitamin A (retinol). Retinol has known functions in cellular differentiation, immune-modulation and activation of carcinogen-metabolising enzymes [76, 77]. Beta-carotene may also participate in host responses to oxidant stress and is hypothesised to protect the host from free radicals that cause DNA damage and the carcinogenic cascade [1].

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Wholegrains, vegetables and fruit](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence for consumption of foods containing beta-carotene was limited but generally consistent. The dose-response meta-analysis of dietary beta-carotene intake showed no significant association, and no significant associations were observed in current, former or never smokers in analyses stratified by smoking status. The analysis of serum beta-carotene showed a significant eight per cent decreased risk of lung cancer per 10 micrograms per 100 millilitres. However, because smoking lowers serum beta-carotene levels, residual confounding cannot be excluded. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that foods containing beta-carotene decreases the risk of lung cancer is limited.

7.7 Foods containing vitamin C

(Also see CUP Lung SLR 2015: Section 5.5.9)

The CUP identified two new studies [39, 53], giving a total of 13 studies (17 publications) reviewing the evidence for foods containing vitamin C and lung cancer (see CUP Lung SLR 2015 Tables 191 and 192 for a full list of references). Of nine studies reporting on lung cancer incidence, six showed inverse associations, three of which were significant. Three studies reported inconsistent results by treatment arm, smoking status or sex when comparing the highest and lowest categories of intake. Three studies reported on lung cancer mortality. Two studies showed inverse associations, one of which was significant. One study reported inverse associations, significant for men only when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 206).

Ten of the 13 studies were included in the dose-response meta-analysis ($n = 4,379$ cases), which showed an eight per cent decreased risk per 40 milligrams per day of vitamin C (RR 0.92 (95% CI 0.88–0.96)) (CUP Lung SLR 2015 Figure 207). There was evidence of high heterogeneity ($I^2 = 66\%$, $p_{\text{heterogeneity}} < 0.01$) that was partially explained in stratified analysis in which the significant inverse association was observed in current

smokers but not in former or never smokers (see CUP Lung SLR 2015 Figure 209). There was evidence of non-linear dose-response ($p < 0.01$). There was a decreasing risk of lung cancer for increasing vitamin C intakes up to approximately 100 milligrams per day, but little additional risk decrease at higher intakes (see CUP Lung SLR 2015 Figure 213 and Table 193).

After stratification by smoking status, the results remained significant in current smokers (13 per cent decreased risk per 40 milligrams per day), but there was no significant association in former or never smokers (see **Table 10** and CUP Lung SLR 2015 Figure 209).

Table 10: Summary of CUP 2015 stratified dose-response meta-analysis – foods containing vitamin C

Analysis	Increment	RR (95% CI)	I ²	No. Studies	No. Cases
Current smokers	Per 40 mg/day	0.87 (0.79–0.96)	62%	4	1,664
Former smokers	Per 40 mg/day	0.96 (0.87–1.05)	0%	3	582
Never smokers	Per 40 mg/day	0.93 (0.79–1.08)	0%	3	225

One study [59] was not included in any of the CUP analyses because it reported insufficient data.

All studies adjusted for intensity, duration of smoking and other smoking variables in addition to smoking status.

The 2005 SLR did not find a significant association and included only two studies in the dose-response meta-analysis. The CUP update includes more studies and cases.

Published pooled analyses and meta-analyses

Results from one published pooled analysis and one published meta-analysis on dietary vitamin C and lung cancer risk were identified in the CUP Lung SLR 2015. The pooled analysis reported non-significant inverse associations for current, former and never smokers. The meta-analysis reported inverse associations for both current and former smokers, significant in current smokers. A non-significant positive association was observed for never smokers. Results from the CUP Lung SLR 2015 and the published pooled analysis are presented in **Table 11**.

Table 11: Summary of CUP 2015 meta-analysis and published pooled-analysis – foods containing vitamin C

Study	Increment/ Contrast	RR (95% CI)	I ²	No. Studies	No. Cases
CUP Lung SLR 2015 (smokers)	Per 40 mg/day	0.87 (0.79–0.96)	62%	4	1,664
Pooling Project (smokers) [82]	Highest vs. lowest	0.85 (0.70–1.02)	-	8*	1,915
*Three studies were included in both the CUP highest vs. lowest analysis and Pooling Project [63, 71, 83].					

No studies on serum vitamin C were identified.

Mechanisms

It is biologically plausible that vitamin C could protect against cancer, but a clear mechanism has not been established in humans. Vitamin C traps free radicals and reactive oxygen molecules, protecting against lipid peroxidation, reducing nitrates and stimulating the immune system [84, 85]. Moreover, it helps to regenerate vitamin E, another antioxidant vitamin [86]. Vitamin C has also been shown to inhibit formation of carcinogens and protect DNA from mutagenic attack in experimental in vitro models [87].

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Wholegrains, vegetables and fruit](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence for consumption of foods containing vitamin C was limited but generally consistent. The dose-response meta-analysis showed a significant decreased risk of lung cancer risk in smokers. Although studies adjusted for smoking and for intensity and duration of smoking, there is the potential for residual confounding due to smoking. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that higher consumption of foods containing vitamin C decreases the risk of lung cancer in current smokers is limited.



7.8 Foods containing isoflavones

(Also see CUP Lung SLR 2015: Section 5.8)

The CUP identified four new studies (five publications) [88–92] reviewing the evidence for foods containing isoflavones and lung cancer (see CUP Lung SLR 2015 Tables 219 and 220 for a full list of references). Of the four studies reporting on lung cancer incidence, three reported non-significant inverse associations and one reported a non-significant inverse association in never smokers, as well as a non-significant positive association in current and former smokers combined, when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 232).

Most studies did not have the information needed for dose response meta-analysis; therefore, only highest versus lowest analysis was performed. All four studies were included in an analysis comparing the highest and lowest consumers of foods containing isoflavones ($n = 2,919$ cases), which showed a significant decreased risk (RR 0.88 (95% CI 0.79–0.99)) (CUP Lung SLR 2015 Figure 232). There was no evidence of heterogeneity ($I^2 = 0\%$).

When the results were stratified by smoking status, they remained significant in never smokers (34 per cent decreased risk when comparing the highest with the lowest consumers). There was no significant association in current or former smokers (see **Table 12** and CUP Lung SLR 2015 Figure 233).

Table 12: Summary of CUP 2015 stratified highest vs. lowest analysis – foods containing isoflavones

Analysis	Contrast	RR (95% CI)	I^2	No. Studies	No. Cases
CUP 2015	Highest vs. lowest	0.88 (0.79–0.99)	0%	4	2,919
CUP 2015 current and former smokers	Highest vs. lowest	1.02 (0.84–1.25)	0%	2	1,054
CUP 2015 never smokers	Highest vs. lowest	0.66 (0.51–0.84)	0%	3	714

All studies included in the analysis were adjusted for smoking status.

No studies were identified in the 2005 SLR.

Published pooled analyses and meta-analyses

Results from two published meta-analyses [89, 93] on dietary isoflavone consumption and lung cancer risk were identified in the CUP Lung SLR 2015. Both analyses reported inverse associations, which were significant when comparing the highest with the lowest levels of intake (RR 0.63 (95% CI 0.45–0.90) [89] and RR 0.80 (95% CI 0.71–0.89) [93]).

Mechanisms

Isoflavones are antioxidants and have been shown to inhibit expression of CYP1A1 (a cytochrome P450 enzyme that helps to metabolise toxins), resulting in decreased formation of reactive carcinogen metabolites that form DNA adducts [94]. Elevated CYP1A1 activity has been associated with increased risk of lung cancer, primarily in smokers [69]. The evidence for interactions between CYP1A1 and flavonoids is supported by the observation that protective associations of flavonoids are associated with specific CYP1A1 genotypes [69, 95]. Isoflavones have diverse effects on cancer cells that may be relevant to lung cancer, but a precise mechanism of action in lung cancer has not been defined.

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Wholegrains, vegetables and fruit](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence for consumption of foods containing isoflavones was limited but generally consistent. The highest versus lowest analysis showed a significant decreased risk of lung cancer. A significant inverse association was also observed in never smokers. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that higher consumption of foods containing isoflavones decreases the risk of lung cancer in individuals who have never smoked is limited.

7.9 Red meat

(Also see CUP Lung SLR 2015: Section 2.5.1.3)

The CUP identified six new studies, giving a total of seven studies (eight publications) [52, 54, 96-100] reviewing the evidence for red meat and lung cancer (see CUP Lung SLR 2015 Tables 67 and 68 for a full list of references). Of five studies reporting on lung cancer incidence, one reported a significant positive association, two reported non-significant positive associations and one reported a non-significant inverse association. One study reported a significant positive association for men and a non-significant positive association for women, when comparing the highest and lowest categories of intake. One study, on lung cancer mortality, reported a borderline significant positive association when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 79).



All seven studies were included in a dose-response meta-analysis ($n = 9,765$ cases), which showed a 22 per cent increased risk per 100 grams per day of red meat (RR 1.22 (95% CI 1.02–1.46)) (CUP Lung SLR 2015 Figure 80). High heterogeneity was observed ($I^2 = 66\%$, $p_{\text{heterogeneity}} < 0.01$) for all studies combined. Visual inspection of the forest plot suggests it is explained by two studies that reported stronger associations than the average: one study in high-risk people participating in a screening for lung cancer [64] and the follow-up of the 1987 National Health Interview Survey with lung cancer mortality as an endpoint [101]. Both studies were adjusted for smoking duration and intensity (see CUP Lung SLR 2015 Figure 80).

When stratified by gender, the results for men showed a 14 per cent increased risk (RR 1.14 (95% CI 1.05–1.24)) and the results for women showed no significant association (RR 1.08 (95% CI 0.90–1.29); see CUP Lung SLR 2015 Figure 82). Four studies reported data stratified by smoking status. Two [97, 101] reported no significant associations, one [99] reported a significant positive association in men who had quit more than 10 years previously and one [64] reported significant positive associations in current and former smokers when comparing the highest with the lowest consumers.

All studies adjusted for intensity and duration, as well as smoking status, except one study [96], which adjusted for smoking in two categories (yes and no).

There was no meta-analysis of cohort studies conducted for the 2005 SLR. The 2005 SLR finding of ‘limited – suggestive increases risk’ was based on case-control studies.

Published pooled analyses and meta-analyses

Results from two published meta-analyses on red meat and lung cancer were identified in the CUP Lung SLR 2015. Both meta-analyses reported significant increased risk, consistent with the CUP Lung SLR 2015. Results from the published meta-analyses are presented in **Table 13**.

Table 13: Summary of CUP 2015 meta-analysis and published meta-analyses – red meat

Study	Increment/ Contrast	RR (95% CI)	I^2	No. Studies	No. Cases
CUP Lung SLR 2015	Per 100 g/day	1.22 (1.02–1.46)	66%	7	9,765
Xue (2014) [102]	Per 120 g/day	1.21 (1.14–1.28)	-	6	7,070
Yang (2012b) [103]	Highest vs. lowest	1.20 (1.10–1.30)	0%	5	9,174

Mechanisms

Red meat contains haem iron, which has been proposed to lead to the production of free radicals. When cooked at high temperatures, red meat can also contain heterocyclic amines and polycyclic aromatic hydrocarbons [1]. However, a specific mechanism linking red meat to lung cancer risk has not been clearly identified.

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Meat, fish and dairy products](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence for consumption of red meat was limited but generally consistent. The dose-response meta-analysis showed a significant increased risk of lung cancer per 100 grams per day. There was evidence of high heterogeneity. No analysis by smoking status was possible, and although studies adjusted for smoking, there is the potential for residual confounding due to smoking. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that consumption of red meat increases the risk of lung cancer is limited.

7.10 Processed meat

(Also see CUP Lung SLR 2015: Section 2.5.1.2)

The CUP identified six new or updated studies (eight publications) [64, 66, 96-100, 104] giving a total of nine studies (11 publications) reviewing the evidence for processed meat and lung cancer (see CUP Lung SLR 2015 Tables 59 and 60 for a full list of references). Of four studies reporting on lung cancer incidence, one reported a non-significant positive association, one reported a non-significant inverse association and two reported inconsistent results for men and women when comparing the highest and lowest categories of intake. Three studies reported on lung cancer mortality: one reported a non-significant inverse association, and two reported inconsistent results for men and women when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 71).

Seven of the nine studies were included in the dose-response meta-analysis ($n = 10,292$ cases), which showed a 14 per cent increased risk per 50 grams per day of processed meat (RR 1.14 (95% CI 1.05–1.24); see CUP Lung SLR 2015 Figure 72). No heterogeneity was observed ($I^2 = 0\%$). When one study that did not adjust for smoking (Iso, 2007) was removed, the results remained similar (RR 1.16 (95% CI 1.07–1.27); see CUP Lung SLR 2015 Figure 73). The observed overall significant positive association was influenced by one large study [99], which contributed 58 per cent of the weight in the analysis; the summary RR was 1.07 (95% CI = 0.94–1.22) when this study was omitted. There was an indication of small study bias with Egger's test ($p = 0.04$; see CUP



Lung SLR 2015 Figure 74), appearing to be due to an absence of small studies showing positive association. There was evidence of a non-linear relationship ($p < 0.01$) with a steeper increase of the curve at lower intake level followed by a plateau (see CUP Lung SLR 2015 Figure 77 and Table 61).

When the results were stratified by outcome, they remained significant for incidence (RR 1.17 (95% CI 1.07–1.27) per 50 grams per day) but showed no significant association for mortality (RR = 0.79 (95% CI 0.56–1.12); see CUP Lung SLR Figure 76). The results for men and women showed no significant associations per 50 grams per day (RR = 1.01 (95% CI 0.73–1.41) and RR = 1.04 (95% CI 0.81–1.35), respectively; see CUP Lung SLR 2015 Figure 75). No analysis by smoking status was possible. Three studies did report data stratified by smoking status. Two [97, 101] reported no significant associations, and one [99] showed significant positive associations in male former (< 10 years) and current smokers when comparing the 90th and the 10th percentiles (RR = 1.31 (95% CI 1.11–1.55) and RR = 1.18 (95% CI 1.04–1.33), respectively).

All studies were adjusted for duration of smoking, intensity or time since quitting, as well as smoking status, apart from two studies: one study on mortality reported a non-significant inverse association [104], and one study adjusted only for smoking status and reported a non-significant positive association [96].

The CUP findings strengthen the results from the 2005 SLR, which showed a non-significant positive association and included only two studies (RR = 1.03 (0.92–1.16). The CUP update includes five more studies and many more cases of lung cancer.

Published pooled analyses and meta-analyses

No published pooled analysis was identified. Results from two published meta-analyses on processed meat and lung cancer were identified in the CUP Lung SLR 2015. Both meta-analyses reported non-significant positive associations. Results from the published meta-analyses are presented in **Table 14**.

Table 14: Summary of CUP 2015 meta-analysis and published meta-analyses – processed meat

Study	Increment/ Contrast	RR (95% CI)	I ²	No. Studies	No. Cases
CUP Lung SLR 2015	Per 50 g/day	1.14 (1.05–1.24)	0%	7	10,292
Xue (2014) [102]	Per 50 g/day	1.09 (0.99–1.19)	-	5	7,070
Yang (2012b) [103]	Highest vs. lowest	1.05 (0.92–1.19)	49%	4	9,174

Mechanisms

N-nitroso compounds are suspected mutagens and carcinogens that are found in processed meats and produced in the stomach from nitrates, including those used to preserve meats [105]. When cooked at high temperatures, meats can also contain heterocyclic amines and polycyclic aromatic hydrocarbons. Haem promotes the formation of *N*-nitroso compounds and also contains iron, which is hypothesised to increase production of free radicals [1]. However, no direct mechanism linking these processes to lung cancer has been identified.

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Meat, fish and dairy products](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence for consumption of processed meat was limited but generally consistent. The dose-response meta-analysis showed a significant increased risk of lung cancer per 50 grams per day. No analysis by smoking status was possible and although the studies adjusted for smoking, there is the potential for residual confounding due to smoking. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that consumption of processed meat increases the risk of lung cancer is limited.

7.11 Foods containing retinol

(Also see CUP Lung SLR 2015: Section 5.5.1.1)

Dietary retinol

The CUP identified one new study [53], giving a total of seven studies. The new study reported no significant association (RR 0.85 (95% CI 0.62–1.16)) when comparing the highest with the lowest categories of intake. The 2005 SLR identified nine studies and showed no significant association between dietary retinol consumption and lung cancer risk in a meta-analysis of three of these studies (RR 1.00 (95% CI 1.00–1.00) per 100 International units per day). No new meta-analysis was conducted.

Serum retinol

The CUP identified two new or updated cohort studies giving a total of 15 studies (20 publications) assessing serum retinol and lung cancer (see CUP Lung SLR 2015 Tables 128 and 129 for a full list of references). Of nine studies reporting on lung cancer incidence, seven reported inverse associations, one of which was significant. Two studies reported inconsistent findings in men and women when comparing the highest and lowest levels. Of two studies reporting on lung cancer mortality, one reported a non-



significant inverse association, and the other reported inconsistent findings in men by age group (≤ 60 or > 60 years) when comparing the highest and lowest levels (see CUP Lung SLR 2015 Figure 153).

Eight studies were included in the dose-response meta-analysis ($n = 2,855$ cases), which showed a three per cent decreased risk per 10 micrograms per 100 millilitres (RR 0.97 (95% CI 0.95–0.98)) (CUP Lung SLR 2015 Figure 154). No heterogeneity was observed ($I^2 = 0\%$). There was evidence of non-linearity ($p < 0.01$) (see CUP Lung SLR 2015 Figure 157 and Table 130). The curve is suggestive of a decreased risk of lung cancer with higher blood retinol levels but may start to plateau after 90 $\mu\text{g}/100\text{ ml}$. No significant association was observed in the Multiethnic cohort [75], where the retinol blood levels were higher than in the other studies.

Three studies [106-108] were not included in any of the CUP analyses because they reported insufficient data.

All studies adjusted for intensity, duration of smoking and other smoking variables, in addition to smoking status, except one study [109] which was adjusted only for smoking status.

The CUP findings, like the 2005 SLR, show an inverse association, but the results in the CUP are significant. The CUP update includes twice the number of studies and 805 more cases of lung cancer.

Published pooled analyses and meta-analyses

No pooled analyses or meta-analyses were identified in the CUP Lung SLR 2015.

Mechanisms

The diverse and complex mechanisms whereby retinoids may have an impact on lung carcinogenesis are not completely understood. Retinol and its metabolites are known to bind to a family of receptors involved in differentiation, membrane structure and function, and immunological effects associated with carcinogenesis [110].

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Other dietary exposures](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence for consumption of foods containing retinol was limited but generally consistent. The dose-response meta-analysis showed a significant decreased risk of lung cancer per 10 micrograms per 100 millilitres for serum retinol. The non-linear analysis suggests a decreased risk of lung cancer at higher blood retinol levels. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that foods containing retinol decrease the risk of lung cancer is limited.

7.12 Alcoholic drinks

(Also see CUP Lung SLR 2015: Sections 5.4, 5.4.1, 5.4.2 and 5.4.3)

The CUP identified 18 new or updated cohort studies [65, 88, 111-126], giving a total of 45 studies (50 publications) assessing alcohol in the form of ethanol and lung cancer (see CUP Lung SLR 2015 Tables 104 and 105 for a full list of references). Of 24 studies reporting on incidence, 14 reported positive associations, two of which were significant. Three studies reported non-significant inverse associations and three reported no effect. Four studies reported inconsistent results for men and women when comparing the highest and lowest categories of intake. Of 12 studies reporting on mortality, seven reported positive associations, two of which were significant. Two reported non-significant inverse associations and one study reported no association. Three studies reported inconsistent results for men and women when comparing the highest and lowest categories of intake (see CUP Lung SLR 2015 Figure 120).

Twenty-six studies were included in the dose-response meta-analysis ($n = 21,940$ cases), which showed a three per cent increased risk per 10 grams of ethanol per day (RR 1.03 (95% CI 1.01–1.05); see CUP Lung SLR 2015 Figure 121. High heterogeneity was observed ($I^2 = 67\%$, $p_{\text{heterogeneity}} < 0.001$) for all studies combined. In meta-regression analysis, year of publication and adjustment for smoking significantly explained heterogeneity, but not geographic location, unit of intake (servings or g/day), sex, outcome or study size. In meta-regression models with both variables, lower RR estimates were found in more recent studies ($p = 0.012$ for those published after 2006 versus before 2002) and with more adjustment for smoking ($p = 0.017$ for more adjusted compared with unadjusted).

There was indication of small study bias with Egger's test ($p = 0.02$) (see CUP Lung SLR 2015 Figure 123). The asymmetry suggests missing small studies on the left side of the plot. Non-linear analysis showed that no increased risk was evident at low levels and risk becoming significantly increased at approximately 40 grams per day of ethanol intake ($p < 0.01$; see CUP Lung SLR 2015 Figure 131 and Table 106). Non-linear analyses were performed for men and women; tests were significant for both ($p < 0.01$; see CUP Lung SLR 2015 Figures 132 and 133 and Tables 107 and 108).

When the results were stratified by smoking status, no significant associations were observed (see CUP Lung SLR 2015 Table 102).

Seven studies [50, 106, 127-131] were not included in any of the CUP analyses because they reported insufficient data.

Four studies did not adjust for smoking; five studies adjusted for smoking status only, 10 studies adjusted for smoking status and intensity (cigarettes per day, pack-years) smoked and 11 studies adjusted for smoking status, intensity and duration (years smoking and/or time since quitting). The studies included in the Pooling Project adjusted for smoking status, smoking duration for past and current smokers, and cigarettes smoked daily for current smokers.



The CUP findings are similar to those from the 2005 SLR, which showed a borderline positive association (RR = 1.02 (95% CI 1.00–1.05)) per 10 grams of ethanol per week, although the CUP meta-analysis reached statistical significance. The CUP update includes 17 more studies and many more cases of lung cancer.

Published pooled analyses and meta-analyses

Results from one published pooled analysis [132] and two published meta-analyses [133, 134] on alcohol and lung cancer were identified by the CUP Lung SLR 2015. In the pooled analysis no significant associations were observed in men or women when comparing the highest with the lowest alcohol consumers. Six of the seven cohorts from this pooled analysis were included in the CUP analysis. When the results from the CUP and the Pooling Project were stratified by smoking status, no significant associations were observed (see CUP Lung SLR 2015 Figure 127). Both meta-analyses reported no significant associations (RR 1.02 (95% CI 0.92–1.28) [133] and RR 1.27 (95% CI 0.85–1.91)) [134].

Results from the CUP Lung SLR 2015 and the published pooled analysis are presented in **Table 15**.

Table 15: Summary of CUP 2015 meta-analysis and published pooled-analysis – ethanol

Study	Increment/ Contrast	RR (95% CI)	I ²	No. Studies	No. Cases
CUP	Per 10 g/day	1.03 (1.01–1.05)	67%	26	21,940
CUP Lung SLR 2015 + pooled analysis	Per 10 g/day	1.03 (1.02–1.05)	67%	32	24,630
Pooled analysis of cohort studies [132]	≥ 30 g/day vs. none – men	1.21 (0.91–1.61)	-	7	3,137
	≥ 30 g/day vs. none – women	1.16 (0.94–1.43)	-		

Other alcohol exposures

Dose-response meta-analyses were conducted for beer, wine and spirits, and lung cancer. No significant associations were observed for beer and spirits, although a significant inverse association was observed for wine and lung cancer. When the studies from the CUP analysis (but not those included in the pooled analysis) were combined with the results from the pooled analysis, a similar pattern emerged (see **Table 16** and CUP Lung SLR 2015 Figures 138, 144, 145, 149 and 150).

Table 16: Summary of CUP dose-response meta-analyses – other alcohol exposures, as ethanol

Analysis	Increment	RR (95% CI)	I ²	No. Studies	No. Cases
CUP 2015 Beer	Per 10 g/day	1.04 (0.93–1.16)	64%	7	3,481
CUP 2015 Wine	Per 10 g/day	0.87 (0.76–0.98)	62%	5	2,701
CUP 2015 Spirits	Per 10 g/day	1.03 (0.98–1.10)	0%	6	2,920

Mechanisms

Reactive metabolites of alcohol such as acetaldehyde are carcinogenic. There is also an interaction with smoking: tobacco may induce specific mutations in DNA that are less efficiently repaired in the presence of alcohol. Alcohol may also function as a solvent, enhancing penetration of other carcinogenic molecules into mucosal cells [135].

In addition, the effects of alcohol may be mediated through the production of prostaglandins, lipid peroxidation and the generation of free radical oxygen species. Last, high consumers of alcohol may have diets low in essential nutrients, making tissues susceptible to carcinogenesis [1].

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Alcoholic drinks](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence was generally consistent, and the dose response meta-analysis showed a significant increased risk per 10 grams of ethanol per day for lung cancer. There was evidence of high heterogeneity, explained by year of publication and adjustment for smoking. There was evidence of non-linearity: no increase was evident at low levels but it became significant at approximately 40 grams per day of ethanol. This pattern was similar in both men and women. It is not possible to exclude residual confounding by smoking. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that consumption of alcoholic drinks increases the risk of lung cancer is limited.



7.13 Physical activity

(Also see CUP Lung SLR 2015: Sections 6.1, 6.1.1.1 and 6.1.1.2)

The CUP identified one new study (one publication) [136], giving a total of five studies (six publications) reviewing the evidence for total physical activity and lung cancer (see CUP Lung SLR 2015 Tables 225 and 226 for a full list of references).

All five studies were included in an analysis comparing the highest and lowest total physical activity levels ($n = 1,457$ cases), which showed no significant association (RR 0.90 (95% CI 0.77–1.04)) (CUP Lung SLR 2015 Figure 234). There was evidence of moderate, but not significant heterogeneity ($I^2 = 40\%$, $p_{\text{heterogeneity}} = 0.10$). When one study [137] that carried 44 per cent of the weight was excluded from the analysis, no heterogeneity was observed and the association became significant (summary RR 0.85 (95% CI 0.72–0.99)).

All studies adjusted for smoking status and intensity.

Published pooled and meta-analyses

One published pooled analysis [138] of cohort studies reporting on total physical activity and lung cancer was identified in the CUP Lung SLR 2015. It reported significant decreased risk of lung cancer in both men and women when comparing the highest with the lowest levels of physical activity (total and leisure time combined) (RR = 0.78 (95% CI 0.73–0.83) and RR = 0.76 (95% CI 0.69–0.84), respectively).

Other physical activity exposures

The CUP Lung SLR 2015 compared highest and lowest levels of occupational and recreational physical activity. No association was observed for occupational physical activity (RR 1.12 (95% CI 0.99–1.28)), a significant inverse association was observed for recreational physical activity (RR 0.86 (95% CI 0.81–0.92)), and no significant association was observed for never smokers (see **Table 17** and Figures 235, 236 and 238 in the CUP Lung SLR 2015), a pattern suggestive of residual confounding by smoking. One published meta-analysis [139] reported significant inverse associations in men, women, heavy and light smokers (see CUP Lung SLR 2015 Table 233).

Table 17: Summary of CUP highest vs. lowest meta-analysis – other physical activity exposures

Analysis	Contrast	RR (95% CI)	I ²	No. Studies	No. Cases
Occupational physical activity	Highest vs. lowest	1.12 (0.99–1.28)	0%	5	3,773
Recreational physical activity	Highest vs. lowest	0.86 (0.81–0.92)	41%	18	17,655
	Highest vs. lowest, current smokers	0.81 (0.71–0.91)	65%	6	6,596
	Highest vs. lowest, former smokers	0.68 (0.51–0.90)	50%	3	3,647
	Highest vs. lowest, never smokers	0.99 (0.76–1.31)	19%	3	894



Mechanisms

The association between physical activity and lung cancer is complex. Unlike many other cancers, lung cancer is not positively associated with BMI. The observed association between physical activity and lung cancer may be a reflection of reverse causation due to chronic lung disease, which is associated with lung cancer risk and limits physical activity. Residual confounding by smoking is also possible, perhaps explaining why leisure activity has an inverse association and occupational activity a positive association. There is evidence showing a lower risk of lung cancer with higher levels of physical activity. Sustained, moderate physical activity raises the metabolic rate and increases maximal oxygen uptake. In the long term, regular periods of such activity increase the body's metabolic efficiency and capacity (the amount of work that it can perform), as well as reducing blood pressure and insulin resistance. The relationship between activity, BMI and lung cancer makes the evidence difficult to interpret. There is limited evidence suggesting that physical activity protects against lung cancer.

Update: As part of the WCRF/AICR Diet, Nutrition, Physical Activity and Cancer: A Global Perspective report, published in 2018, this section on mechanisms has been reviewed and updated. Please see [Exposures: Physical activity](#) (Appendix – Mechanisms) for the updated mechanisms summary.

CUP Panel's conclusion:

The evidence is inconsistent – a significant decreased risk was observed with higher levels of recreational physical activity but an increased risk (non-significant) was observed for occupational physical activity. Although studies in the occupational physical activity analysis adjusted for smoking status, BMI and other confounders, the potential for residual confounding remains. There is evidence for plausible mechanisms operating in humans. The CUP Panel concluded the following:

The evidence suggesting that higher levels of physical activity decrease the risk of lung cancer is limited.

7.14 Other

Other exposures were evaluated. However, data were either of too low quality or too inconsistent, or the number of studies too few to allow conclusions to be reached. This list of exposures judged as 'limited – no conclusion' is summarised in the matrix on **page 8**.

The evidence for foods containing selenium, foods containing quercetin, selenium supplements, total fat, butter, retinol supplements and low body fatness, previously judged as 'limited – suggestive' in the Second Expert Report [1], was less consistent, and the Panel could not draw any conclusions from the updated evidence.

Evidence for the following exposures previously judged as 'limited – no conclusion' in the Second Expert Report remained unchanged after updating the analyses with new data identified in the CUP Lung SLR 2015: pulses (legumes), poultry, fish, eggs, milk and dairy products, coffee, tea, folate, vitamin C supplements, multivitamin supplements, pro-vitamin A carotenoids, lycopene, patterns of diet, body fatness.

The following exposures, which were also previously too limited to draw conclusions in the Second Expert Report and not updated as part of the CUP Lung SLR 2015 owing to a lack of new evidence, remained 'limited – no conclusion': cereals (grains) and their products, starchy tubers; dietary fibre; animal fats; plant oils; soft drinks; preservation, processing, and preparation; carbohydrate; protein; vitamin A; thiamin; riboflavin; niacin; vitamin B6; vitamin E; calcium; copper; iron; zinc; energy intake.

In addition, evidence for the following new exposures, for which no judgement was made in the Second Expert Report, was too limited to draw any conclusions: citrus fruit; total meat; green tea; beta-cryptoxanthin, lutein and zeaxanthin; plasma hydroxyvitamin D; and height.

8. Comparison with the Second Expert Report

More exposures in this CUP update were analysed according to smoking status. Much of the new evidence was on foods containing retinol, beta-carotene, vitamin C and isoflavones, and on alcohol. The updated evidence on fruit and foods containing carotenoids was less strong than in the Second Expert Report [1]. The increase in the amount and quality of the evidence highlighted the need for further research, particularly in non-smokers.

9. Conclusions

The CUP Panel concluded the following:

Convincing evidence

Arsenic in drinking water: Consumption of arsenic in drinking water is a convincing cause of lung cancer.

Beta-carotene supplements: Consumption of high-dose beta-carotene supplements is a convincing cause of lung cancer in current and former smokers.

Limited-suggestive evidence

Vegetables: The evidence suggesting that consumption of vegetables decreases the risk of lung cancer in current and former smokers is limited.

Fruit: The evidence suggesting that consumption of fruit decreases the risk of lung cancer in current and former smokers is limited.

Foods containing carotenoids: The evidence suggesting that foods containing carotenoids decrease the risk of lung cancer is limited.

Foods containing beta-carotene: The evidence suggesting that foods containing beta-carotene decrease the risk of lung cancer is limited.

Foods containing retinol: The evidence suggesting that foods containing retinol decrease the risk of lung cancer is limited.

Foods containing vitamin C: The evidence suggesting that foods containing vitamin C decrease the risk of lung cancer in current smokers is limited.

Foods containing isoflavones: The evidence suggesting that foods containing isoflavones decrease the risk of lung cancer in individuals who have never smoked is limited.

Physical activity: The evidence suggesting that physical activity decreases the risk of lung cancer is limited.

Red meat: The evidence suggesting that consumption of red meat increases the risk of lung cancer is limited.

Processed meat: The evidence suggesting that consumption of processed meat increases the risk of lung cancer is limited.

Alcoholic drinks: The evidence suggesting that consumption of alcoholic drinks increases the risk of lung cancer is limited.

For a full description of the definitions of and criteria for the terminology of ‘convincing’, ‘probable’, ‘limited – suggestive’, ‘limited – no conclusion’ and ‘substantial effect on risk unlikely’, see the **Appendix** on page 67.

The Cancer Prevention Recommendations were reviewed by the CUP Panel and published in 2018. Please see [Recommendations and public health and policy implications](#) for further details.

Each conclusion on the likely causal relationship between an exposure and the risk of cancer forms a part of the overall body of evidence that is considered during the process of making Cancer Prevention Recommendations. Any single conclusion does not represent a recommendation in its own right. The 2018 Cancer Prevention Recommendations are based on a synthesis of all these separate conclusions, as well as other relevant evidence.

Acknowledgements

Panel Members

CHAIR – Alan Jackson CBE MD FRCP
FRCPATH FRCPCH FAFN
University of Southampton
Southampton, UK

DEPUTY CHAIR – Hilary Powers PhD RNutr
University of Sheffield
Sheffield, UK

Elisa Bandera MD PhD
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ, USA

Steven Clinton MD PhD
The Ohio State University
Columbus, OH, USA

Edward Giovannucci MD ScD
Harvard School of Public Health
Boston, MA, USA

Stephen Hursting PhD MPH
University of North Carolina at Chapel Hill
Chapel Hill, NC, USA

Michael Leitzmann MD DrPH
Regensburg University
Regensburg, Germany

Anne McTiernan MD PhD
Fred Hutchinson Cancer Research Center
Seattle, WA, USA

Inger Thune MD PhD
Oslo University Hospital and University
of Tromsø
Oslo and Tromsø, Norway

Ricardo Uauy MD PhD
Instituto de Nutrición y Tecnología
de los Alimentos
Santiago, Chile

Observers

Elio Riboli MD ScM MPH
Imperial College London
London, UK

Isabelle Romieu MD MPH ScD
International Agency for Research
on Cancer
Lyon, France

Research Team

Teresa Norat PhD
Principal Investigator
Imperial College London
London, UK

Doris Chan MSc
Research Associate
Imperial College London
London, UK

Snieguole Vingeliene MSc
Research Associate
Imperial College London
London, UK

Dagfinn Aune MSc
Research Associate
Imperial College London
London, UK

Leila Abar MSc

Research Associate
Imperial College London
London, UK

Ana Rita Vieira MSc

Research Associate
Imperial College London
London, UK

Deborah Navarro-Rosenblatt MSc

Research Associate
Imperial College London
London, UK

Darren Greenwood PhD

Statistical Adviser
Senior Lecturer in Biostatistics
University of Leeds
Leeds, UK

Christophe Stevens

Database Manager
Imperial College London
London, UK

WCRF Executive**Marilyn Gentry**

President
WCRF International

Kelly Browning

Executive Vice President
AICR

Kate Allen PhD

Executive Director
Science and Public Affairs
WCRF International

Deirdre McGinley-Gieser

Senior Vice President for Programs
and Strategic Planning
AICR

Stephenie Lowe

Executive Director
International Financial Services
WCRF Network

Rachael Gormley

Executive Director
Network Operations
WCRF International

Nadia Ameyah

Director
Wereld Kanker Onderzoek Fonds

Secretariat

HEAD – **Rachel Thompson** PhD RNutr
Head of Research Interpretation
WCRF International

Susannah Brown MSc

Science Programme Manager
(Research Evidence)
WCRF International

Stephanie Fay PhD

Science Programme Manager
(Research Interpretation)
WCRF International

Susan Higginbotham PhD RD

Vice President of Research
AICR

Giota Mitrou PhD

Director of Research Funding and
Science External Relations
WCRF International

Martin Wiseman FRCP FRCPATH FAFN

Medical and Scientific Adviser
WCRF International



Abbreviations

AICR	American Institute for Cancer Research
BMI	Body mass index
CI	Confidence interval
CUP	Continuous Update Project
DNA	Deoxyribonucleic acid
IARC	International Agency for Research on Cancer
<i>n</i>	Number of cases
RR	Relative risk
SLR	Systematic literature review
WCRF	World Cancer Research Fund

Glossary

Adenocarcinoma

Cancer of glandular epithelial cells.

Adjustment

A statistical tool for taking into account the effect of known confounders (see confounder).

Antioxidant

A molecule that inhibits the oxidation of other molecules. Oxidation is a chemical reaction involving the loss of electrons, which can produce free radicals. In turn, these radicals can start chain reactions, which can cause damage or death to cells (see free radicals).

Antiproliferative

Of, or relating to, a substance used to prevent or delay the increase in cell numbers characteristic of tumours.

Bias

In epidemiology, consistent deviation of an observed result from the true value in a particular direction (systematic error) due to factors pertaining to the observer or to study design or analysis (see selection bias).

Body mass index (BMI)

Body weight expressed in kilograms divided by the square of height expressed in metres ($\text{BMI} = \text{kg}/\text{m}^2$). Provides an indirect measure of body fatness. Also known as Quetelet's Index.

Carcinogen

Any substance or agent capable of causing cancer.

Case-control study

An epidemiological study in which the participants are chosen on the basis of their disease or condition (cases) or lack of it (controls), to test whether distant or recent history of an exposure such as smoking, genetic profile, alcohol consumption or dietary intake is associated with the risk of disease.

Chronic

A health condition or disease that is persistent or long lasting.

Cohort study

A study of a (usually large) group of people whose characteristics are recorded at recruitment (and sometimes also later), followed up for a period of time during which outcomes of interest are noted. Differences in the frequency of outcomes (such as disease) within the cohort are calculated in relation to different levels of exposure to factors of interest – for example, smoking, alcohol consumption, diet and exercise.

Differences in the likelihood of a particular outcome are presented as the relative risk, comparing one level of exposure to another.

Confidence interval (CI)

A measure of the uncertainty in an estimate, usually reported as a 95 per cent confidence interval (CI), which is the range of values within which there is a 95 per cent chance that the true value lies. For example, the effect of smoking on the relative risk of lung cancer may be expressed as 10 (95% CI 5–15). This means that the estimate of the relative risk was calculated as 10 and that there is a 95% chance that the true value lies between 5 and 15.

Confounder

A variable that is associated both with an exposure and a disease but is not in the causal pathway from the exposure to the disease. If not adjusted for within a specific epidemiological study, this factor may distort the apparent exposure–disease relationship. An example is that smoking is related both to coffee drinking and to risk of lung cancer, and thus unless accounted for (adjusted) in studies, might make coffee drinking appear falsely as a cause of lung cancer.

Deoxyribonucleic acid (DNA)

The double-stranded, helical molecular chain found within the nucleus of each cell, which carries the genetic information.

Dietary fibre

Constituents of plant cell walls that are not digested in the small intestine. Several methods of analysis are used, which identify different components. The many constituents that are variously included in the definitions have different chemical and physiological features that are not easily defined under a single term. The different analytical methods do not generally characterise the physiological impact of foods or diets. Non-starch polysaccharides are a consistent feature and are fermented by colonic bacteria to produce energy and short-chain fatty acids including butyrate. The term ‘dietary fibre’ is increasingly seen as a concept describing a particular aspect of some dietary patterns.

DNA methylation

A process by which methyl groups are added to DNA. DNA methylation is one of several epigenetic mechanisms that regulate gene expression.

Dose-response

A term derived from pharmacology that describes the degree to which an effect changes as the level of an exposure changes, for instance, intake of a drug or food.

Exposure

A factor to which an individual may be exposed to varying degrees, such as intake of a food, level or type of physical activity, or aspect of body composition.

Free radicals

An atom or group of atoms that has one or more unpaired electrons. A prominent feature of radicals is that they have high chemical reactivity, which explains their normal biological activities and how they inflict damage on cells. There are many types of radicals, but those of most importance in biological systems are derived from oxygen and known collectively as reactive oxygen species.

Genotoxic

Chemical agents that damage the genetic information within a cell, causing mutations, which may lead to cancer.

Genotype

Part of the genetic makeup of a cell (DNA sequence), and therefore of an organism or individual, which determines a specific characteristic (phenotype) of that cell, organism or individual.

Heterocyclic amines

Along with polycyclic aromatic hydrocarbons, chemicals formed when muscle meat, including beef, pork, fish or poultry, is cooked using high-temperature methods.

Heterogeneity

A measure of difference between the results of different studies addressing a similar question. In meta-analysis, the degree of heterogeneity may be calculated statistically using the I^2 test.

High-income countries

As defined by the World Bank, countries with a gross national income per capita of more than US \$12,732. This term is more precise than and used in preference to 'economically developed countries'.

Immune response

The production of antibodies or specialised cells in response to foreign proteins or other substances.

Immunomodulation

Encompasses all therapeutic interventions aimed at modifying the immune response.

Incidence rates

The number of new cases of a condition appearing during a specified period of time expressed relative to the size of the population; for example, 60 new cases of breast cancer per 100,000 women per year.

Inflammation

The immunologic response of tissues to injury or infection, characterized by accumulation of white blood cells that produce several bioactive chemicals (cytokines), causing redness, pain, heat and swelling. Inflammation may be acute (such as in response to infection or injury) or chronic (as part of several conditions, including obesity).

Less developed regions

As defined by the IARC, all regions of Africa, Asia (excluding Japan), Latin America and the Caribbean, Melanesia, Micronesia and Polynesia.

Lipid peroxidation

The oxidative degradation of lipids. It is the process in which free radicals ‘steal’ electrons from the lipids in cell membranes, resulting in cell damage.

Meta-analysis

The process of using statistical methods to combine the results of different studies.

Metastasis

Also metastatic disease; the spread of a cancer or other disease from one organ or part of the body to another not directly neighbouring it.

More developed regions

As defined by the IARC, all regions of Europe plus northern America, Australia, New Zealand and Japan.

Mutation

A permanent change of the nucleotide sequence of the genome (an organism’s complete set of DNA).

Nested case-control study

A case-control study in which cases and controls are drawn from the population of a cohort study; often used for studies of prospectively collected information or biological samples.

Non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. It usually grows and spreads more slowly than small-cell lung cancer.

Odds ratio

A measure of the risk of an outcome such as cancer, associated with an exposure of interest, used in case-control studies; approximately equivalent to relative risk.

Oncogene

A gene which in certain circumstances can transform a cell into a tumour cell.

Pathogenesis

The origin and development of disease; the mechanisms by which causal factors increase the risk of disease.

Pooled analysis

In epidemiology, a type of study in which original individual-level data from two or more original studies are obtained, combined and re-analysed.

Processed meat

Meat (usually red meat) that is preserved by smoking, curing or salting, or by the addition of preservatives. Definitions of what precisely is included vary between countries and studies.

Prostaglandins

A group of physiologically active lipid compounds having diverse hormone-like effects in animals.

Randomised controlled trial (RCT)

A study in which a comparison is made between one intervention (often a treatment or prevention strategy) and another (control). Sometimes the control group receives an inactive agent (a placebo). Groups are randomised to one intervention or the other, so that any difference in outcome between the two groups can be ascribed with confidence to the intervention. Sometimes, neither investigators nor subjects know to which intervention they have been randomised; this is called 'double-blinding'.

Relative risk (RR)

The ratio of the rate of an outcome (e.g., disease (incidence) or death (mortality)) among people exposed to a factor, compared with the rate among the unexposed; usually used in cohort studies.

Selection bias

Bias arising from the procedures used to select study participants and from factors influencing participation.

Statistical significance

The probability that any observed result has or has not occurred by chance.

Conventionally, a probability of less than 5 per cent ($p < 0.05$) that a study result has occurred by chance is considered 'statistically significant' (see confidence interval).

Small-cell lung cancer

Small-cell lung cancer (also known as 'small-cell carcinoma') is a highly malignant type of cancer that commonly arises within the lung.

Squamous cell carcinoma

Squamous cell carcinoma is a cancer of squamous cells, one kind of epithelial cell.

Systematic literature review (SLR)

A means of compiling and assessing published evidence that addresses a scientific question with a predefined protocol and transparent methods. May or may not include meta-analysis.

Tumour-suppressor genes

Normal genes that slow down cell division, repair DNA mistakes, or promote apoptosis or programmed cell death. When tumor suppressor gene function is impaired, cells can accumulate errors in DNA that can lead to cancer.

References

1. World Cancer Research Fund/American Institute for Cancer Research. *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective*. Washington DC: AICR, 2007. Available from wcrf.org/about-the-report
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2015; Available from <http://globocan.iarc.fr> 2012.
3. Ginsberg MS, Grewal RK and Heelan RT. Lung cancer. *Radiol Clin North Am* 2007; 45: 21-43.
4. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer–relative risk estimates for the major histological types from a pooled analysis of case-control studies. *Int J Cancer* 2012; 131: 1210-9.
5. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2008; Available from <http://globocan.iarc.fr>. 2012.
6. Ezzati M, Henley SJ, Lopez AD, et al. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. *Int J Cancer* 2005; 116: 963-71.
7. Ezzati M and Lopez AD. Estimates of global mortality attributable to smoking in 2000. *Lancet* 2003; 362: 847-52.
8. Youlten DR, Cramb SM and Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. *J Thorac Oncol* 2008; 3: 819-31.
9. Bray FI and Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. *Int J Cancer* 2010; 126: 1454-66.
10. Peto R LA, Boreham J, Thun M. Mortality from smoking in developed countries 1950-2000. 2nd ed. 2006.
11. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. *J Natl Cancer Inst* 2008; 100: 1672-94.
12. Lam WK, White NW and Chan-Yeung MM. Lung cancer epidemiology and risk factors in Asia and Africa. *Int J Tuberc Lung Dis* 2004; 8: 1045-57.
13. Dela Cruz CS, Tanoue LT and Matthay RA. Lung cancer: epidemiology, etiology, and prevention. *Clin Chest Med* 2011; 32: 605-44.
14. Kenfield SA, Wei EK, Stampfer MJ, et al. Comparison of aspects of smoking among the four histological types of lung cancer. *Tob Control* 2008; 17: 198-204.
15. Lortet-Tieulent J, Soerjomataram I, Ferlay J, et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. *Lung Cancer* 2014; 84: 13-22.
16. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. *Int J Cancer* 2005; 117: 294-9.
17. Janssen-Heijnen ML and Coebergh JW. The changing epidemiology of lung cancer in Europe. *Lung Cancer* 2003; 41: 245-58.
18. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. *Chest* 2005; 128: 452-62.
19. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. *Mayo Clin Proc* 2008; 83: 584-94.
20. American Cancer Society. *Cancer Facts & Figures 2016*. American Cancer Society: Atlanta, 2016.
21. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 2015; 385: 977-1010.
22. Taylor R, Najafi F and Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. *Int J Epidemiol* 2007; 36: 1048-59.
23. Field RW and Withers BL. Occupational and environmental causes of lung cancer. *Clin Chest Med* 2012; 33: 681-703.

24. Hosgood HD, 3rd, Boffetta P, Greenland S, et al. In-home coal and wood use and lung cancer risk: a pooled analysis of the International Lung Cancer Consortium. *Environ Health Perspect* 2010; 118: 1743-7.
25. Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. *Am J Epidemiol* 2012; 176: 573-85.
26. Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. *Am J Epidemiol* 2012; 176: 573-85.
27. Sawada N, Iwasaki M, Inoue M, et al. Dietary arsenic intake and subsequent risk of cancer: the Japan Public Health Center-based (JPHC) Prospective Study. *Cancer Causes Control* 2013; 24: 1403-15.
28. Chen CL, Chiou HY, Hsu LI, et al. Ingested arsenic, characteristics of well water consumption and risk of different histological types of lung cancer in northeastern Taiwan. *Environ Res* 2010; 110: 455-62.
29. Baastrup R, Sorensen M, Balstrom T, et al. Arsenic in drinking-water and risk for cancer in Denmark. *Environ Health Perspect*. 2008; 116: 231-7.
30. Nakadaira H, Endoh K, Katagiri M, et al. Elevated mortality from lung cancer associated with arsenic exposure for a limited duration. *J Occup Environ Med*. 2002; 44: 291-9.
31. Tsuda T, Babazono A, Yamamoto E, et al. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. *Am J Epidemiol*. 1995; 141: 198-209.
32. Tsuda T, Nagira T, Yamamoto M, et al. Malignant neoplasms among residents who drank well water contaminated by arsenic from a king's yellow factory. *J UOEH* 1989; 11 Suppl: 289-301.
33. Chen CJ, Wu MM, Lee SS, et al. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. *Arteriosclerosis* 1988; 8: 452-60.
34. Chen CL, Hsu LI, Chiou HY, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. *JAMA* 2004; 292: 2984-90.
35. Chiou HY, Hsueh YM, Liaw KF, et al. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. *Cancer Res*. 1995; 55: 1296-300.
36. IARC, *IARC Monographs on the Evaluation of Carcinogenic Risk to Humans*. A Review of Human Carcinogens: Arsenic, Metals Fibers and Dusts. 2012, Lyon, France: International Agency for Research on Cancer.
37. Naujokas MF, Anderson B, Ahsan H, et al. The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. *Environ Health Perspect* 2013; 121: 295-302.
38. Lin J, Cook NR, Albert C, et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. *J Natl Cancer Inst*. 2009; 101: 14-23.
39. Roswall N, Olsen A, Christensen J, et al. Source-specific effects of micronutrients in lung cancer prevention. *Lung Cancer* 2009; 67: 275-81.
40. Satia JA, Littman A, Slatore CG, et al. Long-term use of beta-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: results from the VITamins And Lifestyle (VITAL) study. *Am J Epidemiol*. 2009; 169: 815-28.
41. Virtamo J, Pietinen P, Huttunen JK, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. *JAMA* 2003; 290: 476-85.
42. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med* 1996; 334: 1150-5.
43. de Klerk NH, Musk AW, Ambrosini GL, et al. Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. *Int J Cancer* 1998; 75: 362-7.
44. Cook NR, Le IM, Manson JE, et al. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). *Cancer Causes Control* 2000; 11: 617-26.
45. Lee IM, Cook NR, Manson JE, et al. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. *J Natl Cancer Inst*. 1999; 91: 2102-6.
46. Virtamo J, Taylor PR, Kontto J, et al. Effects of alpha-tocopherol and beta-carotene supplementation on cancer incidence and mortality: 18-year postintervention follow-up of the Alpha-tocopherol, Beta-carotene Cancer Prevention Study. *Int J Cancer* 2014; 135: 178-85.

47. Michaud DS, Feskanich D, Rimm EB, et al. Intake of specific carotenoids and risk of lung cancer in 2 prospective US cohorts. *Am J Clin Nutr*. 2000; 72: 990-7.
48. Ratnasinghe DL, Yao SX, Forman M, et al. Gene-environment interactions between the codon 194 polymorphism of XRCC1 and antioxidants influence lung cancer risk. *Anticancer Res* 2003; 23: 627-32.
49. Liu C, Russell RM and Wang XD. Low dose beta-carotene supplementation of ferrets attenuates smoke-induced lung phosphorylation of JNK, p38 MAPK, and p53 proteins. *J Nutr* 2004; 134: 2705-10.
50. Goodman GE, Schaffer S, Omenn GS, et al. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from beta-carotene and retinol efficacy trial. *Cancer Epidemiol Biomarkers Prev*. 2003; 12: 518-26.
51. Bradbury KE, Appleby PN and Key TJ. Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Clin Nutr*. 2014; 100: 394S-8S.
52. Gnagnarella P, Maisonneuve P, Bellomi M, et al. Nutrient intake and nutrient patterns and risk of lung cancer among heavy smokers: results from the COSMOS screening study with annual low-dose CT. *Eur J Epi* 2013; 28: 503-11b.
53. Takata Y, Xiang YB, Yang G, et al. Intakes of fruits, vegetables, and related vitamins and lung cancer risk: results from the Shanghai Men's Health Study (2002-2009). *Nutr Cancer* 2013; 65: 51-61.
54. Takata Y, Cai Q, Beeghly-Fadiel A, et al. Dietary B vitamin and methionine intakes and lung cancer risk among female never smokers in China. *Cancer Causes Control* 2012; 23: 1965-75.
55. Buchner FL, Bueno-de-Mesquita HB, Linseisen J, et al. Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes Control* 2010; 21: 357-71b.
56. George SM, Park Y, Leitzmann MF, et al. Fruit and vegetable intake and risk of cancer: a prospective cohort study. *Am J Clin Nutr*. 2009; 89: 347-53.
57. Wright ME, Park Y, Subar AF, et al. Intakes of fruit, vegetables, and specific botanical groups in relation to lung cancer risk in the NIH-AARP Diet and Health Study. *Am J Epidemiol*. 2008; 168: 1024-34.
58. Wang LD and Hammond EC. Lung cancer, fruit, green salad and vitamin pills. *Chin Med J (Engl)* 1985; 98: 206-10.
59. Kvale G, Bjelke E and Gart JJ. Dietary habits and lung cancer risk. *Int J Cancer* 1983; 31: 397-405.
60. Fu YY, Takezaki T and Tajima K. [Risk factors of lung cancer—follow-up studies in Nagoya Japan]. *Zhonghua Liu Xing Bing Xue Za Zhi* 1997; 18: 328-30.
61. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Fruits, vegetables and lung cancer: a pooled analysis of cohort studies. *Int J Cancer* 2003; 107: 1001-11.
62. Feskanich D, Ziegler RG, Michaud DS, et al. Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. *J Natl Cancer Inst* 2000; 92: 1812-23.
63. Steinmetz KA, Potter JD and Folsom AR. Vegetables, fruit, and lung cancer in the Iowa Women's Health Study. *Cancer Res*. 1993; 53: 536-43.
64. Gnagnarella P, Maisonneuve P, Bellomi M, et al. Red meat, Mediterranean diet and lung cancer risk among heavy smokers in the COSMOS screening study. *Annals of oncology: ESMO* 2013; 24: 2606-11a.
65. Kabat, G C, Miller, et al. Dietary intake of selected B vitamins in relation to risk of major cancers in women. *Br J Cancer* 2008; 99: 816-21a.
66. Pavanello S, Fedeli U, Mastrangelo G, et al. Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study. *Cancer Genet*. 2012; 205: 278-84.
67. Sakoda LC, Loomis MM, Doherty JA, et al. Chromosome 15q24-25.1 variants, diet, and lung cancer susceptibility in cigarette smokers. *Cancer Causes Control* 2011; 22: 449-61.
68. Linseisen J, Rohrmann S, Miller AB, et al. Fruit and vegetable consumption and lung cancer risk: updated information from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer* 2007; 121: 1103-14.

69. Alexandrov K, Cascorbi I, Rojas M, et al. CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. *Carcinogenesis* 2002; 23: 1969-77.
70. Knekt P, Jarvinen R, Teppo L, et al. Role of various carotenoids in lung cancer prevention. *J Natl Cancer Inst.* 1999; 91: 182-4.
71. Bandera EV, Freudenheim JL, Marshall JR, et al. Diet and alcohol consumption and lung cancer risk in the New York State Cohort (United States). *Cancer Causes Control* 1997; 8: 828-40.
72. Wright ME, Mayne ST, Stolzenberg-Solomon RZ, et al. Development of a comprehensive dietary antioxidant index and application to lung cancer risk in a cohort of male smokers. *Am J Epidemiol* 2004; 160: 68-76.
73. Neuhouwer ML, Patterson RE, Thornquist MD, et al. Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). *Cancer Epidemiol Biomarkers Prev.* 2003; 12: 350-8.
74. Gallicchio L, Boyd K, Matanoski G, et al. Carotenoids and the risk of developing lung cancer: a systematic review. *Am J Clin Nutr.* 2008; 88: 372-83.
75. Epplein M, Franke AA, Cooney RV, et al. Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev.* 2009; 18: 1962-70.
76. Abnet CC, Qiao YL, Dawsey SM, et al. Prospective study of serum retinol, beta-carotene, beta-cryptoxanthin, and lutein/zeaxanthin and esophageal and gastric cancers in China. *Cancer Causes Control* 2003; 14: 645-55.
77. van Poppel G and Goldbohm RA. Epidemiologic evidence for beta-carotene and cancer prevention. *Am J Clin Nutr* 1995; 62: 1393s-402s.
78. Paganini-Hill A, Chao A, Ross RK, et al. Vitamin A, beta-carotene, and the risk of cancer: a prospective study. *J Natl Cancer Inst.* 1987; 79: 443-8.
79. Mannisto S, Smith-Warner SA, Spiegelman D, et al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. *Cancer Epidemiol Biomarkers Prev.* 2004; 13: 40-8.
80. Comstock GW, Alberg AJ, Huang HY, et al. The risk of developing lung cancer associated with antioxidants in the blood: ascorbic acid, carotenoids, alpha-tocopherol, selenium, and total peroxyl radical absorbing capacity. *Cancer Epidemiol Biomarkers Prev.* 1997; 6: 907-16.
81. Stahelin HB, Gey KF and Brubacher G. Plasma vitamin C and cancer death: the prospective Basel Study. *Ann N Y Acad Sci* 1987; 498: 124-31.
82. Cho E, Hunter DJ, Spiegelman D, et al. Intakes of vitamins A, C and E and folate and multivitamins and lung cancer: a pooled analysis of 8 prospective studies. *Int J Cancer* 2006; 118: 970-8.
83. Voorrips LE, Goldbohm RA, Brants HA, et al. A prospective cohort study on antioxidant and folate intake and male lung cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2000; 9: 357-65a.
84. Terry P, Lagergren J, Ye W, et al. Antioxidants and cancers of the esophagus and gastric cardia. *Int J Cancer* 2000; 87: 750-4.
85. Lee KW, Lee HJ, Surh YJ, et al. Vitamin C and cancer chemoprevention: reappraisal. *Am J Clin Nutr* 2003; 78: 1074-8.
86. Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. *J Am Coll Nutr* 2003; 22: 18-35.
87. Fountoulakis A, Martin IG, White KL, et al. Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus. *Dig Dis Sci* 2004; 49: 914-9.
88. Butler LM, Montague JA, Koh WP, et al. Fried meat intake is a risk factor for lung adenocarcinoma in a prospective cohort of Chinese men and women in Singapore. *Carcinogenesis* 2013; 34: 1794-9.
89. Yang G, Shu XO, Chow WH, et al. Soy food intake and risk of lung cancer: evidence from the Shanghai Women's Health Study and a meta-analysis. *Am J Epidemiol.* 2012; 176: 846-55.
90. Shimazu T, Inoue M, Sasazuki S, et al. Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan. *Am J Clin Nutr.* 2010; 91: 722-8.
91. Seow A, Koh WP, Wang R, et al. Reproductive variables, soy intake, and lung cancer risk among nonsmoking women in the Singapore Chinese Health Study. *Cancer Epidemiol Biomarkers Prev.* 2009; 18: 821-7.

92. Cutler GJ, Nettleton JA, Ross JA, et al. Dietary flavonoid intake and risk of cancer in postmenopausal women: the Iowa Women's Health Study. *Int J Cancer* 2008; 123: 664-71.
93. Wu SH and Liu Z. Soy food consumption and lung cancer risk: a meta-analysis using a common measure across studies. *Nutr Cancer* 2013; 65: 625-32.
94. Kang ZC, Tsai SJ and Lee H. Quercetin inhibits benzo[a]pyrene-induced DNA adducts in human Hep G2 cells by altering cytochrome P-450 1A1 gene expression. *Nutr Cancer* 1999; 35: 175-9.
95. Le Marchand L, Murphy SP, Hankin JH, et al. Intake of flavonoids and lung cancer. *J Natl Cancer Inst* 2000; 92: 154-60.
96. Wie GA, Cho YA, Kang HH, et al. Red meat consumption is associated with an increased overall cancer risk: a prospective cohort study in Korea. *Br J Nutr.* 2014; 112: 238-47.
97. Linseisen J, Rohrmann S, Bueno-de-Mesquita B, et al. Consumption of meat and fish and risk of lung cancer: results from the European Prospective Investigation into Cancer and Nutrition. *Cancer Causes Control* 2011; 22: 909-18.
98. Tasevska N, Cross AJ, Dodd KW, et al. No effect of meat, meat cooking preferences, meat mutagens or heme iron on lung cancer risk in the prostate, lung, colorectal and ovarian cancer screening trial. *Int J Cancer* 2011; 128: 402-11.
99. Tasevska N, Sinha R, Kipnis V, et al. A prospective study of meat, cooking methods, meat mutagens, heme iron, and lung cancer risks. *Am J Clin Nutr.* 2009; 89: 1884-94.
100. Cross AJ, Leitzmann MF, Gail MH, et al. A prospective study of red and processed meat intake in relation to cancer risk. *PLoS Med.* 2007; 4: e325.
101. Breslow RA, Graubard BI, Sinha R, et al. Diet and lung cancer mortality: a 1987 National Health Interview Survey cohort study. *Cancer Causes Control* 2000; 11: 419-31.
102. Xue XJ, Gao Q, Qiao JH, et al. Red and processed meat consumption and the risk of lung cancer: a dose-response meta-analysis of 33 published studies. *Int J Clin Exp Med.* 2014; 7: 1542-53.
103. Yang WS, Wong MY, Vogtmann E, et al. Meat consumption and risk of lung cancer: evidence from observational studies. *Ann Oncol.* 2012; 23: 3163-70b.
104. Iso H, and Kubota Y. Nutrition and disease in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). *Asia Pac J Ca Prev: APJCP* 2007; 8 Suppl: 35-80.
105. Goldman R and Shields PG. Food mutagens. *J Nutr* 2003; 133 Suppl 3: 965s-73s.
106. Connett JE, Kuller LH, Kjelsberg MO, et al. Relationship between carotenoids and cancer. The Multiple Risk Factor Intervention Trial (MRFIT) Study. *Cancer* 1989; 64: 126-34.
107. Salonen JT, Salonen R, Lappetelainen R, et al. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E: matched case-control analysis of prospective data. *Br Med J (Clin.Res. Ed)* 1985; 290: 417-20.
108. Wald N, Idle M, Boreham J, et al. Low serum-vitamin-A and subsequent risk of cancer. Preliminary results of a prospective study. *Lancet* 1980; 2: 813-5.
109. Alfonso HS, Fritschi L, de Klerk NH, et al. Plasma vitamin concentrations and incidence of mesothelioma and lung cancer in individuals exposed to crocidolite at Wittenoom, Western Australia. *Eur J Cancer Prev.* 2006; 15: 290-4.
110. Levine N and Meyskens FL. Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. *Lancet* 1980; 2: 224-6.
111. Shen C, Schooling CM, Chan WM, et al. Alcohol intake and death from cancer in a prospective Chinese elderly cohort study in Hong Kong. *J Epidemiol Community Health* 2013; 67: 813-20.
112. Lin YS, Caffrey JL, Lin JW, et al. Increased risk of cancer mortality associated with cadmium exposures in older Americans with low zinc intake. *J Toxicol Environ Health A* 2013; 76: 1-15.
113. Jung EJ, Shin A, Park SK, et al. Alcohol consumption and mortality in the Korean Multi-Center Cancer Cohort Study. *J Prev Med Public Health* 2012; 45: 301-8.
114. Yang L, Zhou M, Sherliker P, et al. Alcohol drinking and overall and cause-specific mortality in China: nationally representative prospective study of 220,000 men with 15 years of follow-up. *Int J Epidemiol.* 2012; 41: 1101-13a.
115. Breslow RA, Chen CM, Graubard BI, et al. Prospective study of alcohol consumption quantity and frequency and cancer-specific mortality in the US population. *Am J Epidemiol.* 2011; 174: 1044-53.
116. Chao C, Li Q, Zhang F, et al. Alcohol consumption and risk of lung cancer in the VITamins And Lifestyle Study. *Nutr Cancer* 2011; 63: 880-8.

117. Kim MK, Ko MJ, Han JT, et al. Alcohol consumption and mortality from all-cause and cancers among 1.34 million Koreans: the results from the Korea national health insurance corporation's health examinee cohort in 2000. Alcohol use and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). *Cancer Causes Control* 2010; 21: 2295-302.
118. Laukkanen JA, Pukkala E, Rauramaa R, et al. Cardiorespiratory fitness, lifestyle factors and cancer risk and mortality in Finnish men. *Eur J Cancer* 2010; 46: 355-63.
119. Allen NE, Beral V, Casabonne D, et al. Moderate alcohol intake and cancer incidence in women. *J Natl Cancer Inst.* 2009; 101: 296-305.
120. Thun MJ, Hannan LM and DeLancey JO. Alcohol consumption not associated with lung cancer mortality in lifelong nonsmokers. *Cancer Epidemiol Biomarkers Prev.* 2009; 18: 2269-72.
121. Toriola AT, Kurl S, Laukkanen JA, et al. Does binge drinking increase the risk of lung cancer: results from the Findrink study. *Eur J Public Health* 2009; 19: 389-93.
122. Chao C, Slezak JM, Caan BJ, et al. Alcoholic beverage intake and risk of lung cancer: the California Men's Health Study. *Cancer Epidemiol Biomarkers Prev.* 2008; 17: 2692-9.
123. Kabat GC, Kim M, Hunt JR, et al. Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. *Am J Epidemiol.* 2008; 168: 158-69b.
124. Shimazu T, Inoue M, Sasazuki S, et al. Alcohol and risk of lung cancer among Japanese men: data from a large-scale population-based cohort study, the JPHC study. *Cancer Causes Control* 2008; 19: 1095-102.
125. Ozasa K. Alcohol use and mortality in the Japan Collaborative Cohort Study for Evaluation of Cancer (JACC). *Asia Pac J Ca Prev: APJCP* 2007; 8 Suppl: 81-8.
126. Rohrmann S, Linseisen J, Boshuizen HC, et al. Ethanol intake and risk of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Epidemiol.* 2006; 164: 1103-14.
127. Tamosiunas A, Reklaitiene R, Jureniene K, et al. [Time trends in mortality from malignant tumors and lung cancer during the period 1971-2000 and the risk of death in the middle-aged Kaunas men]. *Medicina (Kaunas)* 2003; 39: 596-603.
128. Jeng YL, Wu MH, Huang HB, et al. The methylenetetrahydrofolate reductase 677C->T polymorphism and lung cancer risk in a Chinese population. *Anticancer Res* 2003; 23: 5149-52.
129. Ratnasinghe D, Forman MR, Tangrea JA, et al. Serum carotenoids are associated with increased lung cancer risk among alcohol drinkers, but not among non-drinkers in a cohort of tin miners. *Alcohol Alcohol* 2000; 35: 355-60.
130. Jensen OM. Cancer risk among Danish male Seventh-Day Adventists and other temperance society members. *J Natl Cancer Inst* 1983; 70: 1011-4.
131. Tuyns AJ and Audigier JC. Double wave cohort increase for oesophageal and laryngeal cancer in France in relation to reduced alcohol consumption during the second world war. *Digestion* 1976; 14: 197-208.
132. Freudenheim JL, Ritz J, Smith-Warner SA, et al. Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. *Am J Clin Nutr.* 2005; 82: 657-67.
133. Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and lung cancer risk in never smokers: a meta-analysis. *Ann Oncol.* 2011; 22: 2631-9.
134. Li Y, Yang H and Cao J. Association between alcohol consumption and cancers in the Chinese population—a systematic review and meta-analysis. *PLoS One.* 2011; 6: e18776.
135. IARC. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.* Alcohol Consumption and Ethyl Carbamate. Volume 96. 2010.
136. Inoue M, Yamamoto S, Kurahashi N, et al. Daily total physical activity level and total cancer risk in men and women: results from a large-scale population-based cohort study in Japan. *Am J Epidemiol* 2008; 168: 391-403.
137. Alfano CM, Klesges RC, Murray DM, et al. Physical activity in relation to all-site and lung cancer incidence and mortality in current and former smokers. *Cancer Epidemiol. Biomarkers Prev.* 2004; 13: 2233-41.
138. Sun JY, Shi L, Gao XD, et al. Physical activity and risk of lung cancer: a meta-analysis of prospective cohort studies. *Asian Pac J Cancer Prev.* 2012; 13: 3143-7.
139. Buffart LM, Singh AS, van Loon EC, et al. Physical activity and the risk of developing lung cancer among smokers: a meta-analysis. *J Sci Med Sport* 2014; 17: 67-71.

Appendix: Criteria for grading evidence for cancer prevention

See also [Judging the evidence](#), section 8.

Adapted from Chapter 3 of the 2007 Second Expert Report. Listed here are the criteria agreed by the Panel that were necessary to support the judgements shown in the matrices. The grades shown here are ‘convincing’, ‘probable’, ‘limited – suggestive’, ‘limited – no conclusion’, and ‘substantial effect on risk unlikely’. In effect, the criteria define these terms.

These criteria were used in a modified form for breast cancer survivors (see CUP Breast cancer survivors report 2014).

CONVINCING (STRONG EVIDENCE)

Evidence strong enough to support a judgement of a convincing causal (or protective) relationship, which justifies making recommendations designed to reduce the risk of cancer. The evidence is robust enough to be unlikely to be modified in the foreseeable future as new evidence accumulates.

All of the following are generally required:

- Evidence from more than one study type.
- Evidence from at least two independent cohort studies.
- No substantial unexplained heterogeneity within or between study types or in different populations relating to the presence or absence of an association, or direction of effect.
- Good-quality studies to exclude with confidence the possibility that the observed association results from random or systematic error, including confounding, measurement error and selection bias.
- Presence of a plausible biological gradient (‘dose-response’) in the association. Such a gradient need not be linear or even in the same direction across the different levels of exposure, so long as this can be explained plausibly.
- Strong and plausible experimental evidence, either from human studies or relevant animal models, that typical human exposures can lead to relevant cancer outcomes.

PROBABLE (STRONG EVIDENCE)

Evidence strong enough to support a judgement of a probable causal (or protective) relationship, which generally justifies recommendations designed to reduce the risk of cancer.

All of the following are generally required:

- Evidence from at least two independent cohort studies or at least five case-control studies.
- No substantial unexplained heterogeneity between or within study types in the presence or absence of an association, or direction of effect.
- Good-quality studies to exclude with confidence the possibility that the observed association results from random or systematic error, including confounding, measurement error and selection bias.
- Evidence for biological plausibility.

LIMITED – SUGGESTIVE

Evidence that is too limited to permit a probable or convincing causal judgement but is suggestive of a direction of effect. The evidence may be limited in amount or by methodological flaws but shows a generally consistent direction of effect. This judgement is broad and includes associations where the evidence falls only slightly below that required to infer a probably causal association through to those where the evidence is only marginally strong enough to identify a direction of effect. This judgement is very rarely sufficient to justify recommendations designed to reduce the risk of cancer; any exceptions to this require special, explicit justification.

All of the following are generally required:

- Evidence from at least two independent cohort studies or at least five case-control studies.
- The direction of effect is generally consistent though some unexplained heterogeneity may be present.
- Evidence for biological plausibility.

LIMITED – NO CONCLUSION

Evidence is so limited that no firm conclusion can be made. This judgement represents an entry level and is intended to allow any exposure for which there are sufficient data to warrant Panel consideration, but where insufficient evidence exists to permit a more definitive grading. This does not necessarily mean a limited quantity of evidence. A body of evidence for a particular exposure might be graded 'limited – no conclusion' for a number of reasons. The evidence may be limited by the amount of evidence in terms of the number of studies available, by inconsistency of direction of effect, by methodological flaws (for example, lack of adjustment for known confounders) or by any combination

of these factors. When an exposure is graded ‘limited – no conclusion’, this does not necessarily indicate that the Panel has judged that there is evidence of no relationship. With further good-quality research, any exposure graded in this way might in the future be shown to increase or decrease the risk of cancer. Where there is sufficient evidence to give confidence that an exposure is unlikely to have an effect on cancer risk, this exposure will be judged ‘substantial effect on risk unlikely’.

There are also many exposures for which there is such limited evidence that no judgement is possible. In these cases, evidence is recorded in the full CUP SLRs on the World Cancer Research Fund International website (dietandcancerreport.org). However, such evidence is usually not included in the summaries.

SUBSTANTIAL EFFECT ON RISK UNLIKELY (STRONG EVIDENCE)

Evidence is strong enough to support a judgement that a particular food, nutrition or physical activity exposure is unlikely to have a substantial causal relation to a cancer outcome. The evidence should be robust enough to be unlikely to be modified in the foreseeable future as new evidence accumulates.

All of the following are generally required:

- Evidence from more than one study type.
- Evidence from at least two independent cohort studies.
- Summary estimate of effect close to 1.0 for comparison of high- versus low-exposure categories.
- No substantial unexplained heterogeneity within or between study types or in different populations.
- Good-quality studies to exclude, with confidence, the possibility that the absence of an observed association results from random or systematic error, including inadequate power, imprecision or error in exposure measurement, inadequate range of exposure, confounding and selection bias.
- Absence of a demonstrable biological gradient (‘dose-response’).
- Absence of strong and plausible experimental evidence, from either human studies or relevant animal models, that typical human exposure levels lead to relevant cancer outcomes.

Factors that might misleadingly imply an absence of effect include imprecision of the exposure assessment, insufficient range of exposure in the study population and inadequate statistical power. Defects such as these and in other study design attributes might lead to a false conclusion of no effect.

The presence of a plausible, relevant biological mechanism does not necessarily rule out a judgement of ‘substantial effect on risk unlikely’. But the presence of robust evidence from appropriate animal models or humans that a specific mechanism exists or that typical exposures can lead to cancer outcomes argues against such a judgement.

Because of the uncertainty inherent in concluding that an exposure has no effect on risk, the criteria used to judge an exposure ‘substantial effect on risk unlikely’ are roughly equivalent to the criteria used with at least a ‘probable’ level of confidence. Conclusions of ‘substantial effect on risk unlikely’ with a lower confidence than this would not be helpful and could overlap with judgements of ‘limited – suggestive’ or ‘limited – no conclusion’.

SPECIAL UPGRADING FACTORS

These are factors that form part of the assessment of the evidence that, when present, can upgrade the judgement reached. An exposure that might be deemed a ‘limited – suggestive’ causal factor in the absence, for example, of a biological gradient, might be upgraded to ‘probable’ if one were present. The application of these factors (listed below) requires judgement, and the way in which these judgements affect the final conclusion in the matrix are stated.

Factors may include the following:

- Presence of a plausible biological gradient (‘dose-response’) in the association. Such a gradient need not be linear or even in the same direction across the different levels of exposure, so long as this can be explained plausibly.
- A particularly large summary effect size (an odds ratio or relative risk of 2.0 or more, depending on the unit of exposure) after appropriate control for confounders.
- Evidence from randomised trials in humans.
- Evidence from appropriately controlled experiments demonstrating one or more plausible and specific mechanisms actually operating in humans.
- Robust and reproducible evidence from experimental studies in appropriate animal models showing that typical human exposures can lead to relevant cancer outcomes.

Our Cancer Prevention Recommendations

Be a healthy weight

Keep your weight within the healthy range and avoid weight gain in adult life

Be physically active

Be physically active as part of everyday life – walk more and sit less

Eat a diet rich in wholegrains, vegetables, fruit and beans

Make wholegrains, vegetables, fruit, and pulses (legumes) such as beans and lentils a major part of your usual daily diet

Limit consumption of ‘fast foods’ and other processed foods high in fat, starches or sugars

Limiting these foods helps control calorie intake and maintain a healthy weight

Limit consumption of red and processed meat

Eat no more than moderate amounts of red meat, such as beef, pork and lamb.
Eat little, if any, processed meat

Limit consumption of sugar sweetened drinks

Drink mostly water and unsweetened drinks

Limit alcohol consumption

For cancer prevention, it's best not to drink alcohol

Do not use supplements for cancer prevention

Aim to meet nutritional needs through diet alone

For mothers: breastfeed your baby, if you can

Breastfeeding is good for both mother and baby

After a cancer diagnosis: follow our Recommendations, if you can

Check with your health professional what is right for you

Not smoking and avoiding other exposure to tobacco and excess sun are also important in reducing cancer risk.

Following these Recommendations is likely to reduce intakes of salt, saturated and trans fats, which together will help prevent other non-communicable diseases.

Managed and produced by:



ISBN (pdf): 978-1-912259-04-5

wcrf.org

twitter.com/wcrfint

facebook.com/wcrfint

wcrf.org/blog

WIRF5CUPLU

© 2018 World Cancer Research Fund International. All rights reserved